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ABSTRACT 
 
Calcific aortic valve disease (CAVD) is the most common etiology of acquired 
aortic valve disease. The early stage is characterized by thickening of the leaflets and 
none or marginal effect on the mechanical properties of the valve, while the end stage 
disease is associated with impaired leaflet motion and resistances to blood flow. These 
conditions are known as aortic valve sclerosis (AVSc) and calcific aortic valve stenosis 
(AVS), respectively. AVSc is present in 25–30% of patients over 65 years of age and in 
up to 40% of those over 75 years of age. Moreover, since AVSc hemodynamics are 
comparable to healthy controls, the presentation of the disease is largely asymptomatic 
and almost 10% of these patients will progress to AVS within 10 years from 
the diagnosis. Patients with severe AVS have a life expectancy of less than 10 years if 
untreated. Currently the main indication for AVS is aortic valve replacement (AVR). 
Over the last decade several clinical trials have been performed to halt the 
progression of CAVD with contradictory results. The early enthusiastic findings 
documenting a reduction in the progression of CAVD have been questioned by later 
randomized studies, which show substantial equivalence between treatments and 
placebo. It has been proposed that CAVD therapy may have been initiated too late in 
the course of the disease to have the desired effect. In conclusion, there is currently no 
definitive therapy supported by prospective and randomized studies to halt or delay the 
progression of CAVD, leaving AVR the treatment of choice. Therefore, the 
identification of high-risk patients at early stages of degeneration will open new 
perspectives for the appropriate timing of therapeutic intervention on future clinical 
trials. 
We implemented in vitro and ex vivo experiments to better characterize the early 
asymptomatic stage of CAVD and to evaluate osteopontin (OPN) as a potential 
biomarker in the progression of this degenerative disease. Moreover, we focused on 
OPN role in valve endothelial cells (VEC) migration, as well as valve interstitial cells 
(VIC) osteoblastic-like activation and biomineralization. Our results supported the 
 iii 
correlation between CAVD progression and increased OPN levels in aortic valve tissue 
and blood. Interestingly, in advance stages of calcification, we demonstrated that the 
overexpressed OPN had different post-translational modification compared to healthy 
controls. Moreover, we analyzed bone morphogenetic protein 4 (BMP4) pathway and 
mechanical tensile stretch as cause of VIC osteogenic-like transdifferentiation and 
calcium accumulation.  
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Chapter 1 
 
Introduction 
 
  
 2 
1.1 The Heart 
The heart is shaped roughly like a cone and consists of four muscular chambers 
(two atria and two ventricles), where the right and the left ventricles are the main 
pumping chambers (Figure 1.1). Starting with the right atrium, the systemic 
deoxygenated blood arrives from the superior and inferior vena cava and it is directed to 
the right ventricle. This ventricle is triangular in shape and its superior aspect forms a 
cone-shaped outflow tract, which leads the blood flow to the pulmonary artery towards 
the lungs. The oxygenated blood return to the hart in the left atrium from the four 
pulmonary veins and it is directed to the left ventricle. This last chamber is 
approximately cone shaped, longer then the right ventricle and pumps the oxygenated 
blood into the systemic circulation towards the aorta. 
Four major valves direct the blood flow in one direction only, from the atria to 
the respective ventricles. The atrioventricular valves (tricuspid and mitral) separate the 
atria and ventricles, whereas the semilunar valves (pulmonic and aortic) separate the 
ventricles from the great arteries (Figure 1.1). 
 
Figure 1.1. Illustration of the anatomy of the human heart. 
Adapted from http://nursingmedic.blogspot.com/2010/11/anatomy-of-heart.html 
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1.1.1 The Cardiac Cycle  
The cardiac cycle consist in the sequence of mechanical and electrical events 
that are responsible for the rhythmic atrial and ventricular contractions, and they occur 
on the right side of the heart as on the left side. The cardiac cycle can be divided in in 
four phases based on ventricles and valves positions: inflow phase, the inlet valve is 
open and the outlet valve is closed; isovolumetric contraction, both valves are open 
with no blood flow; outflow phase, the outlet valve is open and the inlet valve is closed; 
isovolumetric relaxation, both valves are closed, with no blood flow. It is common to 
divides these four phases in two parts, the systole refers to ventricular contraction and 
the diastole refers to ventricular relaxation. Throughout the cardiac cycle the atria 
accept blood returning to the heart and during the diastole the blood passes from the 
atrium to the ventricles through the tricuspid and mitral valves. When the systole occurs 
the atrioventricular valves close and the semilunar valves open allowing the blood to 
proceed from the right and left ventricles to the pulmonary and aorta arteries, 
respectively. 
The cardiac cycle has an average time of 800 ms and the cardiac valves open 
and close approximately 40 million times a year, and more than 3 billion times during 
the average human lifetime1. A common point of failure in the system is the aortic 
valve, since this valve regulates the highest-pressure chamber within the heart2. 
 
1.2  Aortic Valve 
The aortic valve is located in the outflow tract of left ventricle (LV) and 
maintains unidirectional blood flow throughout the cardiac cycle. It provides an open 
tract during systolic period and a close tract during diastole preventing blood 
regurgitation from systemic circulation (Figure 1.2), in healthy patients blood flows 
through the aortic valve accelerating to a peak value of 1.35 ± 0.4m/s (Otto, 2001). The 
aortic vavle should functionally be considered part of the entire left ventricular outflow 
track and be viewed in conjunction with the aortic root3. 
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Figure 1.2. Aortic valve representation. 
Adapted from: http://www.webmd.com/heart-disease/heart-failure/aortic-valve-with-stenosis 
 
The aortic root is a cylinder and extends from the basal attachments of the 
leaflets within the left ventricle to the sinutubular junction. The discrete anatomic 
ventriculo-aortic junction is a circular locus within this root, formed where the 
supporting ventricular structures give way to the fibro-elastic walls of the aortic valvar 
sinuses4 (Figure 1.3). In functional terms, all three sinuses of the root, and their 
contained leaflets, are identical. Anatomically, however, two of the valvar sinuses give 
rise to the coronary arteries and these can be nominated as the right, left and non 
coronary aortic sinuses4. The root provides the supporting structures for the leaflets of 
the aortic valve and forms the bridge between the left ventricle and the ascending aorta. 
The aortic valve is normally composed of three leaflets, which attach to the 
aortic root in a semilunar fashion, ascending to the commissures (where the adjacent 
leaflets come together) ad descending to the basal attachment of each leaflet to the 
aortic wall (Figure 1.3). 
 
Figure 1.3. Aortic root representation. 
Adapted from4: Anderson, R. H. The surgical anatomy of the aortic root. Multimedia Manual of Cardio-
Thoracic Surgery 2007, (2007). 
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The aortic leaflets are flexible structures that come together to seal the valve 
orifice during diastole. Vascularization of the valve is not necessary because the leaflets 
are thin enough for the diffusion of oxygen, nutrients, and waste between the tissue and 
the surrounding blood5. The leaflets are a highly specialized structure divided into three 
functionally specific layers: the fibrosa layer, facing the aorta, rich in densely packed 
collagen in circumferential directions, which provides the strength and stiffness of the 
leaflets and it is responsible for absorbing the diastolic and systolic stresses; the 
ventricularis layer, closest to the left ventricle, composed largely of elastin fibers align 
radially, which can extend in diastole and recoil in systole to minimize the leaflet area; 
and the spongiosa layer, located between the previous two, mainly constitute by 
glycosaminoglycans, which accommodate shear forces of the leaflet during the cardiac 
cycle and allow the outer layers to slide easily over one another during leaflet 
motion3,5,6 (Figure 1.4). The collagen-rich fibrosa, the elastin-rich ventricularis, and the 
glycosaminoglycan-rich spongiosa made up 41%, 29%, and 30% of the whole aortic 
valve tissue, respectively7. 
 
Figure 1.4. Aortic valve structure. 
F = Fibrosa layer; S = Spongiosa layer; V = Ventricularis layer. The fibrosa layer face the aorta while the 
ventricularis layer face the left ventricle. Scale bar is 200 µm. Adapted from8: Chen, J.-H. & Simmons, C. 
A. Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for 
matricellular, matricrine, and matrix mechanics cues. Circ. Res. 108, 1510–1524 (2011). 
 
The ventricularis layer is exposed to rapid, pulsatile, unidirectional shear stress 
(Figure 1.5 left panel), while the fibrosa layer experiences an oscillatory stress9 (Figure 
1.5 right panel). This oscillatory stress has been linked to increase in the expression of 
inflammatory receptors and bone morphogenic proteins (BMPs)10; it also decreases the 
expression of inhibitors of fibrosis and calcification11.  
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Figure 1.5. Hemodynamic flow across the aortic valve. 
Schematic representation of diastole and systole hemodynamics in the aortic root affecting aortic valve 
leaflet. Adapted from12: Rajamannan, N. M. et al. Calcific Aortic Valve Disease: Not Simply a 
Degenerative Process: A Review and Agenda for Research From the National Heart and Lung and Blood 
Institute Aortic Stenosis Working Group * Executive Summary: Calcific Aortic Valve Disease - 2011 
Update. Circulation 124, 1783–1791 (2011). 
 
 
1.2.1  Aortic Valve Cell Populations 
The native aortic valve consists of two types of cells: valve endothelial cells 
(VECs) that cover the surface with a single monolayer, and a heterogeneous population 
called valve interstitial cells (VICs) that reside in the bulk tissue matrix. 
The VECs (Figure 1.6), much like the endothelial cells covering the vasculature, 
serve as a protective lining for the underlying tissue by regulating permeability, 
mediating inflammation, and preventing thrombosis13. Transcriptional profiling of 
vascular versus valve endothelial cells demonstrated significant differences between the 
two cell types in vivo14. VECs are oriented circumferentially across the leaflets and 
perpendicular to the direction of the blood flow, in contrast to vascular endothelium, 
which aligns parallel to the blood flow3,15. In addition, the hemodynamic forces exerted 
on the two sides of the leaflets are different. It has been hypothesized that the 
differences in opposite side endothelium may play a critical role in the typical 
predominant localization of pathologic aortic valve calcification near the outflow 
surface (fibrosa layer)16. 
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Figure 1.6. Valve endothelial cells. 
Immunofluorescence image showing isolated human valve endothelial cells (VEC) at 40x magnification. 
Red signal represent platelet endothelial adhesion molecule (PCAM1) also known as cluster of 
differentiation 31 (CD31). 
 
 The VICs (Figure 1.7) reside within the aortic valve leaflets, where they 
synthesize and maintain the extracellular matrix that forms the tissue architecture6. In 
healthy adult valve, the 95% of VICs have a fibroblast-like phenotype and the rest 5% 
is divided in myofribroblasts-like and smooth muscle cells (SMC)17-21. Studies of the 
interstitial cell population have revealed that there is no particular localization within 
the layers of the leaflet and the VICs are present throughout the tissue20,22,23. VIC 
phenotype is believed to be plastic and reversible, with fibroblasts in healthy valves 
representing the majority of the cells. Fibroblast are a quiescent population (qVIC) that, 
in response to injury or disease, acquire a secretory myofribloblast-like phenotype 
(aVIC)18,24,25, where the principal indicator for aVICs is α-smooth muscle actin 
(SMA)26,27. This process allows the secretion and turn over of extracellular matrix 
(ECM) proteins, which repair the tissue micro-damage and enable the long-term 
durability of the leaflets structure3,17. The local environment (paracrine endothelium-
derived signals)28, the inflammatory cytokines (TGF-β1 and BMPs)29, the biochemical 
and biomechanical properties of the ECM11,30-36, and mechanical stimuli induced by 
hemodynamic forces (normal or pathological stretching of the valve tissue) regulate the 
VIC phenotype and function1,37-40. 
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Figure 1.7. Valve interstitial cells. 
Immunofluorescence image showing isolated human valve interstitial cells (VIC) at 60x magnification. 
Red signal represent alpha smooth muscle actin (SMA). 
 
 
1.3  Calcific Aortic Valve Diseases 
CAVD is a progressive disease that eventually leads to calcification of the aortic 
valve, which causes left ventricular outflow react obstruction. Our understanding of the 
pathophysiology has evolved in the past decades. Previously, valve calcification was 
seen as an inevitable consequence of ageing that only has clinical significance once 
symptoms due to valve obstruction occur41. Today, CAVD is view as the result of an 
active, multi-factorial potentially modifiable pathological process41. 
CAVD is the most common heart valve disease with a prevalence of ≈ 30% in 
adults over 65 years in the sub-clinical asymptomatic form, called aortic valve sclerosis 
(AVSc)42. Importantly, between 16% - 33% of patients with AVSc will progress to 
aortic valve stenosis (AVS)43,44, the most common cause of sudden death among valve 
heart diseases45. Moreover, the incidence of CAVD continues to rise due to the aging 
population46, as such, calcific aortic valve disease has a serious impact on general 
health. 
AVSc in characterized by focal sub-endothelial plaque-like lesions on the aortic 
side of the leaflet that extend to the adjacent fibrosa layer6. Moreover, it has been 
reported a prominent accumulation of low-density lipoprotein (LDL), LDL oxidation 
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and microscopic calcification47-51, resulting in macroscopic, progressive valve 
thickening6. Advance stages of CAVD (AVS) are associated with impaired leaflet 
motion and resistance to blood flow due to the calcium deposition and matrix 
degradation6. Once aortic sclerosis is detectable, the risk of cardiovascular events is 
increased by 50%52. At the onset of mild symptoms, survival deviates considerably 
from the even-free curve, with a dramatic decline in survival with severe symptomatic 
aortic stenosis (Figure 1.8).  
 
Figure 1.8. Aortic valve degeneration: conceptual framework. 
Adapted from12,41: Otto, C. M. Calcific aortic valve disease: outflow obstruction is the end stage of a 
systemic disease process. European Heart Journal 30, 1940–1942 (2009). 
Rajamannan, N. M. et al. Calcific Aortic Valve Disease: Not Simply a Degenerative Process: A Review 
and Agenda for Research From the National Heart and Lung and Blood Institute Aortic Stenosis Working 
Group * Executive Summary: Calcific Aortic Valve Disease - 2011 Update. Circulation 124, 1783–1791 
(2011). 
 
Several evidence suggest that CAVD, due to the pathophysiological similarities 
to atherosclerosis, share many risk factors, such as male gender, age, tobacco use, 
diabetes mellitus, hypercholesterolemia, hypertension, hyperparathyroidism, renal 
disease, decreased bone density, and metabolic syndrome. This overlapping of risk 
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factors has led to the hypothesis that calcific aortic valve disease and atherosclerosis 
have similar etiologies, but there are epidemiological discrepancies. In atherosclerosis, 
the main cell population is represented by SMC, while in the aortic valve the key 
players are the VICs (fibroblasts and myofibroblasts)6. Moreover, calcification occurs 
earlier and in more substantial amount in AVS versus atherosclerotic plaques6. 
Furthermore, only 50% of patients with severe AVS have significant coronary artery 
disease (CAD), and the majority of patients with CAD have no sign of CAVD53. 
An additional major risk factor for CAVD is the presence of a bicuspid aortic 
valve (BAV). BAV disease is one of the most frequent observed congenital heart 
abnormalities affecting 0.5-1.4% of the general population and has a 3:1 male 
predominance54-57. Patients with BAV develop aortic valve calcification at an earlier 
age compared with degenerative tricuspid aortic valve51,58,59 and up to 50% of the adults 
who present with AVS show evidence of BAV disease60. A fairly high incidence of 
familial clustering exists, which suggests autosomal-dominant inheritance with reduce 
penetrance61. The anatomic features of BAV are characterized by smooth cusps margins 
and the fusion of two cusps of unequal size (Figure 1.9). The largest cusp often contains 
a raphe instead of a commissure. The most commonly seen variant of BAV is 
characterized by one raphe between the left and right coronary cusps (L-R BAV), which 
is seen in 70-86% of the BAV cases, whereas the fusion of the right and non-coronary 
cusps (R-N BAV) are observed in 12-28% and the left and non-coronary cusps (L-N 
BAV) in 0.5-3% of the cases62-64. BAV with two aortic sinuses and no raphe is 
uncommon and is called type 061. 
 
Figure 1.9. Schematic representation of bicuspid aortic valve classification. 
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Adapted from63: Sievers, H.-H. & Schmidtke, C. A classification system for the bicuspid aortic valve 
from 304 surgical specimens. The Journal of Thoracic and Cardiovascular Surgery 133, 1226–1233 
(2007). 
 
 
1.3.1  Pathophysiology of Calcific Aortic Valve Disease 
Early aortic lesions seem to be initiated by increased mechanical or decreased 
shear stress, in combination with endothelial dysfunction, followed by lipids deposition. 
Researchers as shown that endothelium subjected to abnormal blood flow seems more 
susceptible to inflammatory cytokines65,66, and more important, high stretch loading 
induces upregulation of pro-inflammatory cytokines expression on the fibrosa layer of 
the aortic valve67. Consequently, monocytes infiltrate the endothelial layer via adhesion 
molecules and differentiate into macrophages. Activated T lymphocytes further increase 
cytokines release, which activate quiescent VICs into myofibroblasts and furthermore in 
osteoblast-like cells, eventually causing calcium deposition42,68,69.  
 Srivatsa70, Mohler71 and Rajamannan72 have described a molecular and cellular 
heterogeneity of the biomineralization process. Osteoblastic-like cells can derive from 
circulating myeloid calcifying cell, circulation osteogenic precursor, endothelial 
progenitor cells, valve endothelial cells, valve interstitial cells, and valve annulus 
chondrocytes (Figure 1.10)73. 
 
Figure 1.10. Possible sources of osteogenic-like cell. 
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Adapted from73: Towler, D. A. Molecular and cellular aspects of calcific aortic valve disease. Circ. Res. 
113, 198–208 (2013). 
 
Cytokines involved in the pro-osteogenic signaling cascade that induce 
osteogenic-like transdifferentiation are part of the Wnt, and Notch signaling family as 
well as of the transforming growth factor (TGF)-β superfamily, including the bone 
morphogenetic proteins (BMPs)73,74, which has been investigated further in the result 
section of this dissertation.  
BMPs are secreted polypeptides, a subgroup of the transforming growth factor 
(TGF)-b superfamily. BMPs elicit their effects through activation of receptor complexes 
composed of type I and type II Ser/Thr kinase receptors75,76. When the ligand binds, the 
type II receptors phosphorylate and activate the type I receptors, which propagate the 
signaling by phosphorylating transcription factors (Smads) (Figure 1.8). The BMP type 
I receptors activate the receptor-activated Smads, which assemble into complexes 
together with the common mediator Smad4 and translocate to the nucleus. Smads can 
modulate gene expression runt-related transcription factor 2 (Runx2), alkaline 
phosphatase (ALP), osteopontin (OPN), and other molecules involved in VIC 
activation, osteoblastic-like transdifferentiation and calcium deposition. This process is 
also regulated by the inhibitory I-Smads, Smad6, and Smad777 (Figure 1.11). BMPs can 
activate non-Smad signaling pathways as well. One of these non-Smad signals is the 
paracrine Wnt/b-catenin relay that promotes ALP expression and matrix 
biomineralization78,79. Moreover, Narisawa80 and Harmey81 have demonstrated that 
ALP is able to induce a robust tissue mineralization by neutralizing natural calcification 
inhibitors, such as inorganic phosphate (Pi) and osteopontin (OPN). 
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Figure 1.11. Schematic representation of BMP4 pathway. 
Adapted from82: Boström, K. I., Rajamannan, N. M. & Towler, D. A. The regulation of valvular and 
vascular sclerosis by osteogenic morphogens. Circ. Res. 109, 564–577 (2011). 
 
 
1.3.2  Diagnosis 
The initial diagnosis of aortic valve stenosis typically is based on detection of a 
systolic murmur followed by echocardiography confirmation. Echocardiography 
provides detailed, non-invasive information about the anatomy and etiology of valve 
disease, and the severity of valve stenosis. The first step in evaluation is the assessment 
of valve anatomy by two-dimensional (2D) imaging. Transthoracic imaging provides 
diagnostic images in the vast majority of patients with valve heart disease and is the 
standard approach both for the initial evaluation and for follow-up studies. 
Transesophageal imaging is reserved for patients for whom transthoracic images are 
non-diagnostic or when higher resolution images are needed for clinical decision-
making. Three-dimensional (3D) echocardiographic (3DE) imaging represents a major 
innovation in cardiovascular ultrasound. Advancements in computer and transducer 
technologies permit real-time 3DE acquisition and presentation of cardiac structures 
from any spatial point of view83. Standard measures of aortic stenosis severity are the 
maximum velocity (Vmax) across the stenotic valve, the mean transaortic pressure 
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gradient (ΔPmean) calculated with the Bernoulli equation, and the functional aortic 
valve area (AVA) calculated with the continuity equation (Table 1.1) 84,85. 
AVSc is related to thickening of the aortic cusps without obstruction to blood 
flow (Figure 1.12). The sclerotic lesions of the aortic valve have both similarities and 
differences when compared with the atherosclerotic process. Similarities include 
inflammatory cell infiltrates, oxidized low-density lipoprotein, and calcification, while 
differences between the 2 processes involve a larger calcium load and the absence of 
smooth muscle cell infiltration in aortic valve sclerosis as compared with coronary 
vessels47,72,86-89. The progressive degeneration of the aortic valve leads to the 
obstruction of the left ventricular outflow tract due to impaired leaflet motion and 
resistance to the blood flow, which causes several physiological changes and the 
symptoms of aortic valve stenosis arise.  
 
 Figure 1.12. Calcific aortic valve degeneration phases. 
Histological staining showing cell content and structure architectire (H&E and MOVAT) in different 
stage of CAVD. Lower panels show representative images of 2D echocardiography in controls, aortic 
valve sclerosis and stenosis patients. 
Adapted from90: Grau, J. B. et al. Analysis of osteopontin levels for the identification of asymptomatic 
patients with calcific aortic valve disease. Ann. Thorac. Surg. 93, 79–86 (2012). 
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Table 1.1 Classification of Calcific Aortic Valve Disease 
 Valve Anatomy Aortic Velocity (m/s) 
Mean Gradient 
(mmHg) 
Aortic Valve 
Area (cm2) 
Normal Aortic Valve Transparent leaflets with normal motion < 2.5 < 10 > 2.5 
Aortic Sclerosis Focal leaflet thickening with normal motion < 2.5 < 10 > 2.5 
Mild Aortic Stenosis 
Mild leaflet thickening 
with mildly reduced 
motion 
2.5 – 3 10 – 20 1.5 – 2.5 
Moderate Aortic 
Stenosis 
Mild to moderate calcium 
presence with moderately 
reduced leaflet motion 
3 – 4 20 – 40 1.0 – 1.5 
Severe Aortic 
Stenosis 
Moderate to severe 
calcium presence with 
little leaflet motion 
4 – 5 40 – 60 0.6 – 1.0 
Critical Aortic 
Stenosis 
Severe calcium presence 
with immobile leaflets > 5 > 60 < 0.6 
 
Adapted from84: Lindman, B. R., Bonow, R. O. & Otto, C. M. Current management of calcific aortic 
stenosis. Circ. Res. 113, 223–237 (2013). 
 
 
1.4  Surgical Treatments of Aortic Valve Stenosis  
1.4.1  Aortic Valve Replacement 
Currently in developed countries, the main indication for aortic valve stenosis 
due to CAVD is aortic valve replacement (AVR)91. Patients with severe AVS have a 
life expectancy of less than 10 years if untreated and if there is concomitant heart 
failure, 50% will die within a year92,93. Surgical AVR is the only effective treatment for 
severe AVS and has transformed the outlook of patients presenting this disease84. The 
timing of intervention is critical and is determined through specific guidelines (Figure 
1.13). 
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Figure 1.13. Approach to the diagnosis of calcific aortic valve disease. 
Adapted from84: Lindman, B. R., Bonow, R. O. & Otto, C. M. Current management of calcific aortic 
stenosis. Circ. Res. 113, 223–237 (2013). 
 
Today, isolated AVR can be accomplished with a mini-sternotomy; although a 
full sternotomy is often performed if extensive concomitant coronary artery bypass 
grafting (CABG) is required84. The operative mortality associated with AVR is 
dependent on both patient risk factors and the skill and experience of the surgical team. 
Comorbidities associated with higher 30-day mortality include age, left ventricle 
dysfunction, concomitant coronary artery disease (CAD), previous CABG, renal 
insufficiency, and chronic pulmonary disease84. The mortality associated with AVR has 
decreased dramatically during the past 2 decades and 30-day mortality is currently 
under 3% for isolated AVR and under 4.5% for combined AVR/CABG94,95. 
In elderly and high-risk individual, the risk of death undergoing surgical aortic 
valve replacement is too high, for this reason transcatheter aortic valve implantation 
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(TAVI) has become an exciting treatment option96,97. In a very high-risk population, 
TAVI resulted in 30.7% in mortality at 1 year and in 43.3% mortality at 2 years, where 
standard surgical therapy had a 50.7% and 68.0% mortality at 1 and 2 years, 
respectively98. 
 
1.4.2  Prosthetic Aortic Valves 
Various alternatives are available for aortic valve replacement, and matching 
patients to the most-appropriate type of valve is not always straightforward. Matching 
the right valve for the right patient is a difficult but essential process to optimize the 
outcome for patients undergoing AVR99. The most important factors that should be 
considered in the first place are the patient’s age, life expectancy, preference, 
indication/contraindication for warfarin therapy, and comorbidities (Figure 1.14)99.  
 
Figure 1.14. Flowchart for optimal prosthesis selection. 
Adapted from99: Pibarot, P. & Dumesnil, J. G. Prosthetic Heart Valves: Selection of the Optimal 
Prosthesis and Long-Term Management. Circulation 119, 1034–1048 (2009). 
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Commercially, there are two types of aortic valve prosthesis: mechanical and 
bioprosthetic (Figure 1.15). The mechanical valves currently in use are of a bileaflet 
design, these valves are durable but require lifelong anticoagulation with warfarin. 
Bioprosthetic valves do not require oral anticoagulation, but with limited durability, 10 
to 15 year is the average lifespan100. Bioprosthetic heart valves are made with 
glutaraldehyde-fixed porcine aortic valves, or constructed with glutaraldehyde-fixed 
bovine pericardium and most of the times mounted on stent100. Other types of 
bioprosthetic valves are pulmonary autograft and aortic valve homograft. The former, 
also known as Ross procedure101, is used in young patients, particularly women in 
childbearing years, might not wish to take oral anticoagulation therapy100. The latter is 
less in use because the realization that a homograft aortic valve has limited durability, is 
technically difficult to implant, is expensive to procure and cryopreserve, and might not 
be superior to other bioprosthetic valves102-106. 
 
Figure 1.15. Types of prosthetic valves. 
(A) Bileaflet mechanical valve (St Jude); (B) monoleaflet mechanical valve (Medtronic Hall); (C) caged 
ball valve (Starr-Edwards); (D) stented porcine bioprosthesis (Medtronic Mosaic); (E) stented pericardial 
bioprosthesis (Carpentier-Edwards Magna); (F) stentless porcine bioprosthesis (Medtronic Freestyle); (G) 
percutaneous bioprosthesis expanded over a balloon (Edwards Sapien); (H) self-expandable percutaneous 
bioprosthesis (CoreValve). 
Adapted from: Pibarot, P. & Dumesnil, J. G. Prosthetic Heart Valves: Selection of the Optimal Prosthesis 
and Long-Term Management. Circulation 119, 1034–1048 (2009). 
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Mechanical prostheses have an excellent durability, and structural valve 
degeneration (SVD) is extremely rare with contemporary valves, although the rate of 
SVD in bioprosthetic valves increases over time, particularly after the initial 7 to 8 
years after implantation99. Bioprosthetic SVD is strongly influenced by the age of the 
patient at the time of implantation and the rate of failure is less than 10% at 10 years in 
elderly patients (more than 70 years of age), but is between 20% and 30% in patients 
older than 40 years107,108.  
It is important to note that, despite surgical treatments, the underlying 
mechanism of the valve degeneration is left untreated, and calcification reoccurs even in 
bioprosthetic valves. The pathogenesis of structural degeneration can occur due to 
several processes. The degenerative process of bioprosthetic valves could occur because 
of the tissue fixation with glutaraldehyde, this induces a calcium influx as a result of 
membrane damage, which provides, along with the residual phospholipids of the 
membranes, an environment prone to calcium crystal nucleation108. The immune 
process could occur because bioprosthetic valves are not in fact completely 
“immunologically inert”109 and residual animal antigens could elicit humoral and 
cellular immune responses, leading to tissue mineralization and/or disruption. The only 
available treatment for SVD is reoperation with surgical AVR or TAVI (valve-in-valve 
implantation). 
 
1.5  Pharmacological Treatments of Aortic Valve Stenosis 
Therapeutic strategies able to reduce or halt the progression of CAVD are 
needed to delay and possibly avoid surgical valve replacement. Furthermore, The need 
for alternatives to surgery is emphasized by the increasing age of the general population 
and the rising prevalence of CAVD. Since CAVD and atherosclerosis have similar 
disease progression and risk factors, pharmacological treatment of patients with CAVD 
has been focused on 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors (statins) and angiotensin-converting enzyme inhibitors (ACEi) 110,111. Statins 
are used to inhibit the cholesterol synthesis in the liver and lowering plasma cholesterol 
levels, while ACEi interfere with the renin-angiotensin system blocking the conversion 
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of angiotensin I to angiotensin II causing dilation of blood vessels with consequent 
decrease in blood pressure and improved endothelial function112. 
Several studies have been investigating statin treatment on the progression of 
CAVD. The early enthusiastic findings of observational studies (retrospective and non-
randomized) documenting a reduction in the progression of the disorder have been 
seriously questioned by later, randomized studies, which showed substantial 
equivalence between statin and placebo-treated patients (Table 1.2)113. In conclusion, 
there is currently no definitive therapy supported by prospective and randomized studies 
to halt or delay the progression of CAVD. 
 
Table 1.2 Published nonrandomized and randomized statin trials 
Study (y) Follow Up Grade, AS at baseline Pro statins 
Non Randomized    
Aronow (2001) 2.75 y Mild Yes (p < 0.01) 
Navaro (2001) 1.75 y Mild to moderate Yes (p < 0.03) 
Bellamy (2002) 3.7 y Mild to moderate Yes (p < 0.04) 
Shavelle (2002) 2.5 y N.A. Yes (p < 0.006) 
Rosenhek (2004) 2.0 y Mild to severe Yes (p < 0.0001) 
RAAVE (2007 1.4 y Moderate to severe Yes (p < 0.007) 
    
Randomized    
SALTIRE (2005) 2.08 y Mild to severe No 
SEAS (2008) 4.35 y Mild to moderate No 
ASTRONOMER (2010) 3.5 y Mild to moderate No 
 
Adapted from114,115: Hermans, H. et al. Statins for calcific aortic valve stenosis: into oblivion after 
SALTIRE and SEAS? An extensive review from bench to bedside. Curr Probl Cardiol 35, 284–306 
(2010). 
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Chan, K. L. et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of 
the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. 
Circulation 121, 306–314 (2010). 
 
 The questions that were raised after the results of the randomized statin trials 
where related to the target choose and the timing of intervention. A recent study has 
been published on the genetic associations with valve calcification and aortic 
stenosis116. In this study Thanassoulis et al.116 found a strong correlation between one 
single-nucleotide polymorphism (SNP) in the lipoprotein(a) (LPA) locus and the 
presence of aortic valve calcification, answering the question regarding the use of the 
statins in CAVD patients. The reason of the statin therapy failure could be due to the 
patient population selected for the randomized trials. The patients did have not 
dyslipidemia as facilitating factor for the progression of the disease, so the effect would 
only depend on the pleiotropic effects of statins. Moreover, only patients with at least 
moderate stenosis where included, as such the hemodynamic changes and inflammation 
could be self-perpetuating and overcome the beneficial effect of the statins114. 
 The efficacy of statin therapy should be tested in earlier stages of the disease 
when the aortic valve functions are still in the normal range and the valve degeneration 
is still at the initial stage. The same problems have been notice with ACEi treatment to 
preventing the progression of CAVD117. Although these data are discouraging, there are 
already few studies that demonstrate the potential of statin and ACEi treatments in 
slowing the progression of CAVD at the sclerotic stage118-120. 
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2.1 Reagents 
2.1.1 Media and chemicals 
Advanced Dulbecco’s Modified Eagle’s Medium (DMEM), alpha Minimum 
Essential Medium (MEM), Medium 200 (M200), Phosphate buffered saline (PBS), and 
low serum growth supplement (LSGS) (Life Technologies, Carlsbad, CA). Fetal bovine 
serum (FBS) (Thermo Scientific, Hudson, NH), penicillin, streptomycin, L-glutamine, 
amphotericin B, sodium deoxycholate, and glutathione sepharose high performance 
(Life Technologies, Carlsbad, CA). Type II collagenase, hyaluronidase (Worthington 
Biochemical Corp., Worthington, VA), Trizol (Invitrogen, Carlsbad, CA), platinum pfx 
DNA polymerase (Applied Biosystems, Carlsbad, CA), and Fast SYBR Green Master 
Mix (Life Technologies, Carlsbad, CA). Hydrogen peroxide (H2O2), methanol, ethanol, 
xylene, formalin buffered solution, chloridric acid (HCl), sodium hydroxide (NaOH), 
diethyl pyrocarbonate (DEPC), ascorbic acid, dexamethasone, β-glycerophosphate, 
Alizarin red S, Hematoxylin and Eosin (H&E), proteinase K, UO126, and pravastatin 
(Sigma-Aldrich, St. Louis, MO). Fast red (Vector Laboratories, Burlingame, CA), 
streptavidin-HRP solution, 3,3′-diaminobenzidine (Life Technologies, Carlsbad, CA), 
Proteoprep Blue Albumin and IgG depletion kit (Sigma-Aldrich, St. Louis, MO), and 
BCA protein assay (Thermo Scientific, Waltham, MA).  
 
2.1.2 Antibodies and Proteins 
Neutralizing antibody anti-osteopontin (NAb OPN), neutralizing antibody anti-
vascular endothelial growth factor (NAb VEGF) (R&D systems, Minneapolis, MN), 
antibody anti-phospho-extracellular signal-related kinase 1/2 (Ab pERK1/2), antibody 
anti-platelet endothelial cell adhesion molecule (Ab PECAM1), antibody anti-protein 
kinase B (Ab Akt), and antibody anti-phospho-Akt (Ab pAkt) (Cell Signal, Beverly, 
MA). Neutralizing antibody anti-αvβ3 (Ab αvβ3) (Millipore, Billerica, MA), 
Neutralizing antibody anti-cluster of differentiation 44 (CD44) (Ab CD44) (Ancell, 
Bayport, MN), antibody anti-ERK (Ab ERK), secondary antibody goat anti-
rabbit/mouse horseradish peroxidase-conjugated (HRP) (Santa Cruz Biotechnology, 
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SantaCruz, CA), antibody anti-rabbit Alexa Fluor 488-conjugated, and antibody anti-
mouse Alexa Fluor 568-conjugated (Life Technologies, Carlsbad, CA). 
Type I collagen (BD Biosciences, Sparks, MD), recombinant bone 
morphogenetic protein 4 (BMP4), recombinant Noggin (NOG), recombinant VEGF, 
and recombinant OPN (Peprotech, Rocky Hill, NJ). 
 
2.2 Tissues and Cells 
2.2.1 Echocardiography evaluation 
A certified echocardiographer evaluated all patients enrolled by M-mode, two-
dimensional and Color Doppler echocardiographic assessment. All measurements were 
performed according to the American Society of echocardiography recommendations. 
A single cardiologist assessed the aortic valve calcification assigning a calcium score: 1 
- no calcification; 2 - mildly calcified (small isolated spots); 3 - moderately calcified 
(multiple larger spots); 4 - severely calcified (extensive thickening and calcification of 
all cusps). 
 
2.2.2 Aortic valve collection 
Aortic valves from control and aortic sclerosis patients were obtained through 
collaborations with The Gift of Life Donor Program and the heart transplant research 
program at the University of Pennsylvania Perelman School of Medicine. Stenotic 
aortic valves were collected through the University of Pennsylvania Perelman School of 
Medicine Surgery Department. All patients were enrolled in the protocol #80934 
following Institutional Review Board (IRB) approved guidelines. For each patient 
informed consent was obtained and all the clinical information were collected by patient 
interview and chart review. 
The exclusion criteria used for the study are the following: presence of bicuspid 
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aortic valve, premature menopause and/or osteoporosis, prior aortic valve surgery, 
rheumatic heart disease, endocarditis, active malignancy, chronic liver failure, calcium 
regulation disorders (hyperparathyroidism, hyperthyroidism, and hypothyroidism), 
serum creatinine ≥ 1.5 mg/dl, and chronic or acute inflammatory states (sepsis, 
autoimmune disease, and inflammatory bowel disease). 
 
2.2.3 Valve endothelial cell and valve interstitial cell isolation 
Aortic valve endothelial and interstitial cells were isolated by mechanical 
disruption and enzymatic digestion. After the explant the leaflets were placed in 
complete DMEM containing 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 4 
mM L-glutamine, 1 µg/ml amphotericin B, and 0.82 µg/ml sodium deoxycholate. 
Within 6 hours the leaflets were washed in 1X PBS, then placed in a tube containing 
complete DMEM with 2 mg/ml type II collagenase and incubated in a shaker for 20 
minutes at 37°C. The valve endothelial cells (VEC) were collected by wiping the leaflet 
surfaces with sterile cotton swabs and plating them in complete M200. After removing 
the endothelial layer the specimens were finely minced and place over night at 37°C in 
a tube containing complete DMEM with 1 mg/ml type II collagenase and 100 U/ml 
hyaluronidase. The resulting valve interstitial cells (VIC) were seeded in tissue culture 
plates in complete DMEM and maintained at 37°C and 5% CO2. All the experiments 
were performed on cultured cells between the second and sixth passage. All the cells 
were tested for PECAM1 presence to confirming the purity or absence of endothelial 
cells. 
 
2.4 Molecular Biology Techniques 
2.4.1 RNA isolation 
Extraction of RNA was performed using the RNeasy Fibrous tissue kit 
(QIAGEN, Valencia, CA) homogenizing the entire aortic valve leaflets and Trizol 
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reagent for cultured cells. RNA concentrations were measured spectrophotometrically 
at 260 nm with NanoDrop 2000 (Thermo Scientific, Wilmington, DE). Only high 
quality (absorbance ratio A260/A280 > 1.8) was utilized for two steps PCR 
amplification or stored at -80°C for further analysis.  
 
2.4.2 Reverse Transcription and Real Time Polymerase Chain Reaction 
Reverse transcriptase polymerase chain reaction (RT-PCR) kit (Applied 
Biosystems, Carlsbad, CA) was used to synthesize the complementary DNA from total 
RNA samples. PCR was performed using platinum pfx DNA polymerase (Applied 
Biosystems, Carlsbad, CA) to evaluate the presence or absence of CD44 variants. Real 
Time PCR (qPCR) (Fast SYBR Green Master Mix) was used to calculate the relative 
expression of genes and dissociation curves were generated after each run to control 
proper primer behavior. 18S gene expression was used for normalization. The primers 
used for the analysis are listed in the Appendix A (Table 1). 
Complementary DNA was also analyzed with the RT2 Profiler PCR Array 
(SABioscience, Valencia, CA) for the detection of the expression of 84 human 
extracellular matrix and adhesion molecules (Appendix A, Table 2) following the 
manufacturer’s instructions. 
 
2.4.3 Immunohistochemistry 
Immunohistochemistry analyses of the aortic valve tissues were perform using 
standard protocols from the Pathology Laboratory of the University Of Pennsylvania 
Perelman School of Medicine. The structure of the leaflets was checked by H&E and 
modified Movat pentachrome staining (dark red – nuclei; dark violet – elastic fiber; 
yellow – collagen fibers; blue – proteoglycans). Alizarin Red staining was performed to 
visualize the amount of calcium present on the aortic valves. Histological staining for 
specific antibody (dilution 1:50 – 1:200) was carried out using standard protocols and 
parafﬁn embedded section were stained using the detection kit from DAKO (Glostrup, 
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Denmark).  
 
2.4.4 Immunofluorescence 
Immunofluorescence staining were used to evaluate protein expression in tissues 
and cells using a standard protocol. The primary antibodies were specific for the 
interested proteins with a dilution ranging from 1:50 to 1:2000 and the secondary 
antibody Alexa Fluor dye-conjugated with a dilution of 1:200. Confocal microscope 
Olympus Fluoview 1000 was used to capture the images and the software ImageJ 
(National Institute of Health) was use to quantify the staining. 
 
2.4.5 Western blot 
Western blot analysis was carried out to assess protein expression using specific 
primary antibody (dilution 1:500 – 1:200) and secondary antibody HRP-conjugated 
(dilution 1:5000) following a standard protocol. The autoradiography films were 
developed with a Kodak M35 X-Omat processor and the images were analyzed using 
the software ImageJ. 
 
2.4.6 TUNEL assay 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was 
used to determine apoptotic cells. Paraffin-embedded tissue sections were dewaxed in 
xylene, and then rehydrated through a graded series of ethanol and distilled water. 
Sections were then permeabilized by proteinase K treatment and subsequently 
incubated with TUNEL reaction mixture (Promega, Madison, WI) in a humidified 
chamber. The blocking was performed in 0.3% H2O2 in methanol followed by 
incubation with streptavidin-HRP solution, 3,3′-diaminobenzidine solution, and HRP- 
coupled anti-mouse IgG staining. A negative control using all reagents except terminal 
transferase was performed in parallel. Confocal microscope Olympus Fluoview 1000 
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was used to capture the images and the software ImageJ was use to quantify the 
staining. 
 
2.4.7 In situ hybridization 
Total OPN and its isoforms mRNA was visualized by in situ mRNA 
hybridization method using probes purchased from Exiqon (Woburn, MA). In situ 
hybridization kit from Biochain (Hayward, CA) was used to perform the detection 
steps. Paraffin-embedded sections were deparaffinazed by xylene washes and 
rehydration was obtained through graded ethanol solutions. The sections were fixed 
with 4% formalin buffered solution in DEPC-PBS and proteinase K (10 µg/ml) was 
used for the permeabilization of the tissue sections. After several washes with DEPC-
PBS the sections were incubated with pre-hybridization solution and then hybridize 
with hybridization solution + digoxigenin labeled probe (5 µg/ml). For the detection 
AP-conjugates anti-digoxigenin antibodies were used and the developing solution (NTB 
and CIP into Alkaline Phosphatase Buffer) allowed us to visualize were the probes 
hybridized with the targeted mRNA sequence. Fast red counterstaining was used to 
visualize the nuclei. 
 
2.4.8 ELISA assay 
Blood samples were collected from the subjects before they underwent surgical 
intervention and plasma was separated through centrifugation. Plasma analyses were 
carried out using ELISA method kit to evaluate OPN (R&D, Minneapolis, MN), Fetuin 
A (Biovendor Research & Diagnostic Products, Chandlier, NC), NT-proBNP (Phoenix 
Pharmaceuticals, Burlingame, CA), Parathyroid hormone (IBL America, Minneapolis, 
MN), ADMA (ALPCO Diagnostics, Salem, NH). Estimation of tissue OPN was carried 
out using ELISA kit purchased from Biovendor LLC (Candler, NC). The 
manufacturer’s protocols were followed to process and analyze the samples, absorbance 
was measured using the ELx 808 Ultra Micro plate reader (Bio Tek Instruments Inc., 
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USA) and the concentrations were calculated using the 4-parameter logarithm using the 
KC Junior software (Bio Tek Instruments Inc., Winooski, VT). 
 
2.4.9 In Situ Proximity Ligation Assay 
In situ proximity ligation assay (PLA) kit was purchased from Olink Bioscience 
(Uppsala, Sweeden). The assay was performed following manufacturer instructions. 
Briefly, cells were grown on glass coverslips until ≈80% confluence, then were treated 
with 100 ng/ml BMP4 in presence or absence of 5 ng/ml neutralizing antibody anti 
CD44 (NAb CD44). At the end of the treatments the cells were fixed with cold 
methanol. The cells were then incubated with isoform-specific antibodies anti CD44 
together with antibody anti OPN overnight at 4°C with gentle agitation. After primary 
antibody incubation cells were rinse and PLUS / MINUS secondary PLA probes against 
rabbit and mouse IgG were added and incubated at 37°C for 1 hour with gentle 
agitation. In the end of the incubation with secondary antibodies cells were incubated 
with ligation mixture for 30 minutes at 37°C, following amplification mixture was 
applied for 100 minutes at 37°C. Finally, coverslips were mounted on microscope slides 
with Doulink Mounting Medium and the cells were photographed and analyzed using 
confocal microscope Olympus Fluoview 1000 and the software ImageJ. 
 
2.5 Tensile Stretch Bioreactor 
2.5.1 Bioreactor design and tissue preparation 
Two chambers and one moving piston compose the bioreactor; each chamber 
has 8 media baths and each bath has one stationary pin press-fit into the bottom for 
tissue anchorage. The moving arm is connected to the other pin and to the central 
motorized piston. 
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Figure 2.1. Tensile stretch bioreactor design. 
(A) Preparation of leaflet tissue strips. (B) Configuration of testing sample in tension bioreactor. 
Adapted from: Poggio, P. et al. Noggin attenuates the osteogenic activation of human valve interstitial 
cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
 
The aortic valve leaflets were collected in the operating room and place 
immediately in complete DMEM. Each leaflet was trimmed to form a strip, measuring 
20 mm circumferentially and 8 mm radially. The endothelial layer was preserve limiting 
the tissue handling to the edges. Two springs were threaded at the short extremities of 
each tissue strip and then inserted in the tension bioreactor. The experiments had 
duration of 6 days and 5 ml of osteogenic media (OS) (DMEM/F12 containing 10% 
FBS, 100 U/ml penicillin, 100 µg/ml streptomycin, 4 mM L-glutamine, 1 µg/ml 
amphotericin B, and 0.82 µg/ml sodium deoxycholate, 284 mM ascorbic acid, 10 nm 
Dexamethasone, and 10 mM β-glycerophosphate) ± BMP4 (100 ng/ml) ± NOG (500 
ng/ml) were added fresh every 3 days. As internal control we used leaflet place in the 
bioreactor but without activating the motorized piston. At the end of the experiment the 
tissues strips were removed and divided in two pieces, one embedded in OCT for 
preparing frozen sections and the other for RNA isolation. 
 
2.5.1 Aortic valve tissue engineering 
Porcine Aortic valve leaflets were a gift from the Gorman Cardiovascular 
Research Group at University of Pennsylvania. The leaflets were collected in saline 
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solution for transportation and treated with antibiotic (10 KU/ml penicillin and 10 
mg/ml streptomycin) for 48 hours for sterilization. Decellularization of the leaflets was 
carried put by incubation with 0.25% trypsin for 24 hours at 37°C. The decellularized 
porcine scaffold were then seeded with VICs isolated from aortic sclerosis patients at a 
density of 500,000 cells/cm2 and grown for 3 days, then flipped and seeding was 
repeated on the other side of the leaflets. The final recellularized leaflets were then used 
in static and dynamic conditions in the tension bioreactor as described for the human 
aortic valves.  
 
2.6 In vitro assays 
2.6.1 Calcification assay 
The ability to form hydroxyapatite crystal was tested in smooth muscle cells 
(SMC) and VIC derived from control, sclerotic and stenotic aortic valves. Cells were 
plated and grown in complete DMEM until they reached ~80% conﬂuency. During the 
calcification assay the cells were cultured in complete alpha MEM supplemented with 3 
mM phosphate buffer and the media was replaced every other day. At the endpoint the 
cells were washed briefly in 1X PBS and incubated overnight in 0.6 M HCL at 4°C. 
Calcium levels were estimated with a colorimetric assay using ELx 808 Ultra Micro 
plate reader with a absorbance wavelength at 575 nm. Normalization of total calcium 
content was carried out harvesting the cells in 1 M NaOH and estimating the total 
proteins with the BCA protein assay. Final amount of calcium was expressed as mg of 
calcium over mg of total proteins. Moreover, pictures of each well at different time 
points were taken using an inverted microscope (Hitech Instruments, Inc., Broomall, 
CA). 
 
2.6.3 Wound healing assay 
Migration ability was tested on human umbilical vein endothelial cells 
(HUVEC) in complete M200 with 10% LSGS in combination with different proteins 
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and molecules. A wound was created in conﬂuent plates by using a sterile 200 ml tip 
and the complete M200 was replaced with M200 containing low FBS (0.5%). Wound 
closure was monitored in the presence or absence of 50 ng/ml OPN, 50 ng/ml (p)OPN, 
Neutralizing 10 mg/ml Ab anti-αvβ3, 10 mg/ml NAb anti-CD44 or 10 nM UO126. 
After wounding, cell migration was estimated by image analysis using an inverted 
Olympus CK2 microscope and the wound closure was determined, with ImageJ 
analysis, as the difference between the wound width at 0 and 24 hours. 
 
2.6.4 Angiogenesis assay 
The ability to form new vessel was tested on excised human aortic valve in a 3 
dimensional (3D) collagen structure under 30 ng/ml VEGF, 50 ng/ml OPN, 50 ng/ml 
(p)OPN, 10 mM UO126, 10 mg/ml NAb CD44, 10 mg/ml NAb αvβ3, 10 mg/ml NAb 
OPN, or 10 mg/ml NAb VEGF. Type I collagen was suspended in DMEM and 0.01 
mM NaOH and the resulting solution was titrated with 0.1 M NaOH to pH 7.4. The 
excised tissues (1 mm2) were embedded in type I collagen solution and allowed to 
polymerize in an incubator at 37°C. Complete M200 was added after the complete 
collagen polymerization, the media was changed every other day and photos were taken 
with an inverted microscope every 3 days until the end of the experiments. 
 
2.7 Osteopontin preparation and analysis 
2.7.1 Recombinant osteopontin preparation 
Three vector pDEST490 containing the OPN isoforms a, b and c were purchased 
from Addgene (Cambridge, MA). The open reading frame coding for OPN isoforms 
was excised from the pDEST490 vectors using restriction enzymes (BamHI and SmaI, 
Cell Signal, Beverly, MA) and ligated into the pGEX-5x-2 vector (GE healthcare; 
Piscataway, NJ). The pGEX vector was chosen because contain the FLAG tag and the 
Glutathione S-transferase (GST) tag. The pGEx vectors were transformed into 
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BL21(DE3) competent E. Coli (Life Technologies, Carlsbad, CA) to express large 
amount of OPN isoform. Using the GST tag the OPN isoforms were purified with 
glutathione sepharose following the manufacturer’s instructions. 
 
2.7.2 Circulating osteopontin purification 
Purification of osteopontin from plasma samples was achieved by a two-step 
purification protocol. The first step was the removal of the large amount of human 
serum albumin (HAS) and the major subclasses of gamma globulin (IgG) from the 
plasma. The Proteoprep Blue Albumin and IgG depletion kit was used twice on each 
plasma sample. After HSA/IgG removal, plasma samples were incubated with Ab OPN 
and then incubated with protein A agarose beads to immunoprecipitate the protein of 
interest. Purchased recombinant OPN and non immune-IgG were used as controls. 
 
2.8 Statistical analysis 
The statistical analysis was performed using the SPSS 21 and Prism 6 software. 
Continuous variables were expressed as mean ± standard deviation or mean ± standard 
error of mean. Pearson chi-square and t test was used to evaluate categorical variables 
and Mann Whitney test was used for continuous variables. Comparisons between more 
than two groups were performed using ANOVA test and Kruskal-Wallis test. A value 
of p < 0.05 was considered to be statistically significant.  
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Chapter 3 
 
Osteopontin Levels Correlate With The Progression Of 
Calcific Aortic Valve Disease 
 
Part of this chapter has been published as1,2: 
Paolo Poggio*, Juan B. Grau*, Rachana Sainger, William J. Vernick, William F. 
Seefried, Emanuela Branchetti, Benjamin C. Field, Joseph E. Bavaria, Michael A. 
Acker, and Giovanni Ferrari. Analysis of Osteopontin levels for the identification of 
asymptomatic patients with calcific aortic valve disease. The Annals of Thoracic 
Surgery 93, 79–86 (2012). * These authors contributed equally to this work. 
 
Rachana Sainger, Juan B. Grau, Paolo Poggio, Emanuela Branchetti, Joseph E. 
Bavaria, Joseph H. Gorman III, Robert C. Gorman, and Giovanni Ferrari. 
Dephosphorylation of circulation human Osteopontin correlates with severe valvular 
calcification in patients with calcific aortic valve disease. Biomarkers 17, 111–118 
(2012). 
 
  
 48 
3.1 Introduction 
Aortic valve sclerosis (AVSc) is related to thickening of the aortic leaflets 
without obstruction of the left ventricular outflow. However, the presence of AVSc has 
been associated with a higher risk of cardiovascular events, including increased 
mortality3-5. Therefore, identifying asymptomatic patients that express markers 
associated with calcification will allow us to label them as at high risk to have a rapid 
evolution of calcific aortic valve disease (CAVD). In addition, the identification of 
high-risk patients at early stages of degeneration will open new perspectives for the 
appropriate timing of therapeutic intervention on future clinical trials. 
Osteopontin (OPN) is a multifunctional glycol-phospho-protein that is known 
for its regulatory function in bone remodeling. OPN is involved in a myriad of 
processes, including inflammation and in the inhibition of biomineralization of 
dystrophic and ectopic sites6. OPN, also named secreted phosphoprotein-1 (SPP1), is 
encoded by the SPP1 gene, which is transcribed into three splicing variants, OPN-a, -b, 
and -c. The presence of a fourth splicing variant, called OPN-d, has recently been 
reported, however no details have been provided yet, and therefore it was not included 
in this study7. OPN-a encodes the full-length protein, whereas isoforms b and c result 
from alternative splicing7. The 5’ canonical translation start codon generates a protein 
that includes an N-terminal signal sequence that diverts it to the secretory vesicles, 
whereas a downstream start codon generates a shorter protein that localizes to the 
cytoplasm. 
It has been previously reported that circulating OPN levels are elevated in aortic 
valve stenosis (AVS) patients when compared to healthy controls6. Since the biological 
function of OPN is to regulate calcium deposition8, it has been proposed that the 
increasing levels of OPN in diseased tissue reflects a compensatory mechanism linked 
to loss of function due to transcriptional / post-translational changes or protein-protein 
interactions. We hypothesized that plasma and tissue OPN levels were elevated in 
AVSc patients, before signs of aortic valve calcification and before aortic valve area 
changes. We evaluated the expression of tissue and plasma OPN levels in control, 
AVSc and AVS patients. Furthermore, we analyzed the OPN isoforms differential 
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expression and OPN post-translational modifications. By correlating OPN levels and 
progression of CAVD we aimed to provide a novel tool for the identification of 
asymptomatic patients. 
 
3.2 Results 
3.2.1 Baseline patient characteristic 
 The analysis was carried out with 56 controls, 50 AVSc and 51 AVS patients. 
Controls and AVSc patients had no significant difference in age, while AVS patients 
were significantly older. All the clinical details regarding the patient population used for 
this part of the study are summarized in Table 3.1. 
 
Table 3.1 Patient demographics and Clinical details. 
Demographics 
Controls 
N-56 
Aortic sclerosis 
N=50 
Aortic stenosis 
N=51 
Age (in years) 62.8 ± 2.2 64.6 ± 1.4 76.16 ± 8.26 
Male 29 (51.7%) 30 (60.0%) 29 (56.9%) 
Smokers 19 (33.9%) 20 (40.0%) 20 (39.2%) 
Diabetes 15 (26.8%) 09 (18.0%) 15 (29.4%) 
Hypertension 39 (69.6%) 23 (46.0%) 38 (74.5%) 
Cerebral Vascular Accident 1 (1.6%)) 1 (1.96%) 01 (2.0%) 
Peripheral vascular disease 4 (7.1%) 4 (7.8%) 04 (8.0%) 
Hyperlipidemia 29 (51.8%) 16 (31.4%) 28 (54.9%) 
Coronary artery disease 17 (35.6%) 15 (29.4%) 17 (29.4%) 
 
Adapted from1: Grau, J. B. et al. Analysis of osteopontin levels for the identification of asymptomatic 
patients with calcific aortic valve disease. Ann. Thorac. Surg. 93, 79–86 (2012). 
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3.2.2 Tissue osteopontin levels correlate with the progression of calcific 
aortic valve disease 
We analyzed the expression level of OPN in the tissue of patients with AVSc 
and AVS compared to healthy controls. The tissue histology analysis confirmed the 
thickening of the aortic leaflets in the pathological stages and the presence of 
calcification only in AVS patients (Figure 3.1A). We notice that OPN expression 
increased from control to aortic sclerosis to aortic stenosis (Figure 3.1A). Notably, the 
highest levels of OPN were noted surrounding the areas of highest calcification, on the 
aortic side of the leaflets. To evaluate the correlation between early stages of valve 
degeneration with increasing OPN levels, we performed qPCR and Elisa analyses on 
the tissue of our three cohorts of patients (Figure 3.1B). We were able to confirm the 
correlation between the pathological stages of CAVD and the levels of OPN. 
 
Figure 3.1. Osteopontin levels correlate with the progression of calcific aortic valve 
disease. 
(A) Longitudinal sections of human aortic valve leaflet stained with alizarin red (Alz. Red) and 
immunostaining for OPN (10x magnification). (B) Bar graphs representing quantification of osteopontin 
analyzed by ELISA and qPCR. For qPCR analysis, OPN levels were normalized against the control level. 
* p < 0.05. Adapted from1: Grau, J. B. et al. Analysis of osteopontin levels for the identification of 
asymptomatic patients with calcific aortic valve disease. Ann. Thorac. Surg. 93, 79–86 (2012). 
 51 
3.2.3 Plasma osteopontin levels correlate with the progression of calcific 
aortic valve disease 
Patients with signs of AVSc are at higher risk of developing AVS and other 
cardiovascular complications3-5. Thus, there is the necessity to identify a series of 
molecular markers able to label asymptomatic patients before the disease proceed to the 
final stage. We therefore analyzed the OPN levels in the blood of our cohorts of patients 
in correlation with the presence or absence of signs of biomineralization detectable with 
Transesophageal echocardiography (TEE) reading. A calcium score was assigned to 
each patient on a scale of 1 to 4 based on the method described by Rosenhek et al.9, 
where 1 is absence of calcium, 2, 3 and 4 correspond to mild, moderate and severe 
calcification, respectively (Chapter 2). OPN levels correlated with the presence of 
calcium deposition on the aortic leaflets (Figure 3.2A). Interestingly, all the patients 
evaluated with calcium score 3 or 4 had non-functional valves and were classified as 
having AVS. Patients with mild calcification were classified as having AVSc due to the 
normal function of the aortic valve measured by peak velocity and aortic valve area. It 
is important to note that the group labeled with calcium score 1 included both the 
controls and the AVSc patients with no calcium appearance. This group is of the most 
importance since it generates the question if OPN levels in AVSc patients, with no signs 
of biomineralization, were higher then in the control group. We therefore conducted a 
comparative analysis between five groups: controls with calcium score 1, AVSc with 
calcium score 1 and 2, and AVS with calcium score 3 and 4. Remarkably, OPN levels 
were elevated in asymptomatic AVSc patients with no appearance of calcification 
detected during TEE evaluation (Figure 3.2B). These results suggest that OPN could be 
used as an early marker of CAVD, since its circulating and tissue levels are elevated in 
AVSc asymptomatic patient even before signs of biomineralization are detectable by 
TEE reading.  
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Figure 3.2. Comparison between echocardiographic evaluation and osteopontin 
levels in patients with calcific aortic valve disease. 
(A) Bar graph representing absolute OPN levels, measured by ELISA, in the plasma of patients with 
different calcium scores. (B) Bar graph representing absolute OPN levels, measured by ELISA, in the 
plasma of control group (calcium score 1) and patients (calcium score 1 to 4). (C = control; ASc = aortic 
sclerosis; AS = aortic stenosis). * p < 0.05. Adapted from1: Grau, J. B. et al. Analysis of osteopontin 
levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann. Thorac. 
Surg. 93, 79–86 (2012). 
 
 
3.2.4 Differential expression of osteopontin splicing variant in calcific 
aortic valve disease 
 In the attempt to better characterize OPN as a biomarker for the early stage of 
CAVD, we investigated the OPN splicing variants in the aortic valve tissue (Figure 
3.3A). We therefore analyzed by qPCR the differential expression of OPN splicing 
variants in the controls, the AVSc, and the AVS patients. OPN splicing variants -a, -b 
and -c were overexpressed in the pathological stages (both AVSc and AVS). 
Interestingly, the expression profiles of the three isoforms were different in AVSc 
compared to AVS: OPN-a was increased significantly only at early stages of the 
disease; OPN-b was increased progressively from AVSc to AVS; while OPN-c labeled 
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both of the pathological stages. Due to the overall small group of patients, we cannot 
conclude that the splicing variants profile could be use a biomarker itself, however the 
analysis prompts us to further investigate the tissue localization and biological function 
of the OPN splicing variants. OPN-a, -b, and -c in situ hybridization experiments with 
specific probes for the isoforms confirm increasing levels of OPN mRNAs in the aortic 
valve tissue of control, AVSc and AVS. These results show a differential pattern 
expression of OPN splicing variants in human CAVD tissues. 
 
Figure 3.3. Differential expression of osteopontin splicing variant in calcific aortic 
valve disease. 
 (A) Graphic representation of OPN splicing variants. (B) Relative quantification of OPN-a, OPN-b, 
OPN-c by qPCR. * p < 0.05. (C) Tissue distribution of OPN isoforms detected by in situ hybridization 
(100x magnification). Adapted from1: Grau, J. B. et al. Analysis of osteopontin levels for the 
identification of asymptomatic patients with calcific aortic valve disease. Ann. Thorac. Surg. 93, 79–86 
(2012). 
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3.2.5 Purification of osteopontin from human plasma 
To better characterize the circulating OPN, we decided to purify the OPN from 
control and end stage patient blood for consecutive post-translational modification 
analysis. Because of large excess of human serum albumin (HSA) and other proteins in 
plasma, OPN analysis were carried out implementing immunoprecipitation techniques 
and subsequent evaluation by Western blot (Figure 3.4A). We performed two-step 
purification: the first step removed HSA and IgG; the second step was the 
immunoprecipitation of OPN. The purified protein was eluted from the beads in 
different fractions using acid elution buffer (Figure 3.4B). The same purification 
protocol was used for plasma derived from controls and AVS patients (Figure 3.4C). 
Western blot analysis of purified OPN reviled two bands from plasma of AVS patients. 
This different pattern could be explained by a differential post-translational 
modification of the protein in AVS patients. 
 
Figure 3.4 Circulating OPN purification. 
(A) Representative pattern for osteopontin purification from CAVD patients and healthy controls. 50 ng 
of recombinant OPN was used as a positive control (Lane 1). Total plasma (Lane 2) was depleted of HSA 
and IgG using ProteoSeek Albumin/IgG Removal Kit (Lane 3) and then used for OPN 
Immunoprecipitation with a specific OPN antibody (Lane 4). (E) Western blot showing different fractions 
collected during sample elution. (F) Western blot of purified OPN from CAVD patients and controls. 
Arrows indicates double bands. Adapted from2: Sainger, R. et al. Dephosphorylation of circulating 
human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve 
disease. Biomarkers 17, 111–118 (2012). 
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3.2.6 Phosphorylated osteopontin labels healthy controls 
Since we noticed a different pattern in the Western blot analysis from AVS 
compared to controls, we decided to investigate the phosphorylation status of OPN. We 
evaluated the possible phosphorylation sites using Netphos 2.0 Software, which 
predicted 34 serine, 2 threonine and 2 tyrosine on the OPN sequence (Figure 3.5A). 
Currently there are no specific antibodies that recognize the phosphorylation sites of 
OPN. We evaluate OPN post-translational modification by Western blot using 
antibodies anti phospho-serine, -threonine and -tyrosine on the immunoprecipitated 
OPN. Circulating OPN from controls was phosphorylated in serine, threonine and 
tyrosine, while OPN purified from AVS patients showed a lack of phosphorylation in 
tyrosine (Figure 3.5B and C). Serine and threonine phosphorylation levels where 
comparable between the two groups. 
 
Figure 3.5. Differential post-translational modification of human circulating 
osteopontin from controls and calcific aortic valve disease patients. 
(A) Analysis of osteopontin protein using NetPhos 2.0 Server to predict serine, threonine and tyrosine 
phosphorylation sites. (B) Representative Western blots of phospho-serine, phospho-tyrosine and 
phospho-threonine on purified OPN from controls and CAVD patients. (B) Densitometry of Western 
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blots of phospho-serine, phospho-tyrosine and phospho-threonine on purified OPN from controls and 
CAVD patients. Adapted from2: Sainger, R. et al. Dephosphorylation of circulating human osteopontin 
correlates with severe valvular calcification in patients with calcific aortic valve disease. Biomarkers 17, 
111–118 (2012). 
 
 
3.3 Discussion 
The presence of AVSc has been suggested as a marker of increased 
cardiovascular risk10. Based on this hypothesis, the presence of AVSc may prompt 
clinicians towards more aggressive prevention strategies, although this approach has not 
been tested in a larger prospective clinical trial. In this chapter it is presented a 
translational, interdisciplinary research study aimed to correlate echocardiographic 
evaluation with the differential expression of OPN levels for the identification of 
patients with asymptomatic AVSc. Overall our experiments provided several novel 
messages for the identification of asymptomatic patients with CAVD: patients with 
AVS and AVSc had higher OPN levels compared with controls. OPN level was 
elevated in asymptomatic AVSc patients with no appearance of calcification (bright 
echoes) during TEE evaluation. Moreover, OPN splicing variants -a, -b, and -c were 
differentially expressed during CAVD progression. Interestingly, plasma OPN isolated 
from AVS patients was characterized by a loss of phosphorylation in tyrosine, 
suggesting that not only the levels could be associated with the progression of CAVD.  
As a future clinical implication, the analysis of the differential expression of 
OPN splicing variants during CAVD may help in developing diagnostic strategies to 
follow the progression of asymptomatic aortic valve degeneration. A molecular tool for 
the early detection of AVSc patients could therefore implement the choice of the ideal 
timing for therapeutic intervention either using statins or other drugs.   
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Chapter 4 
 
Role Of Osteopontin In Endothelial Cell Migration 
 
Part of this chapter has been published as1: 
Paolo Poggio, Juan B. Grau, Benjamin C. Field, Rachana Sainger, William F. Seefried, 
Flavio Rizzolio, and Giovanni Ferrari. Osteopontin controls endothelial cell migration 
in vitro and in excised human valve tissue from patients with calcific aortic stenosis and 
controls. Journal of Cellular Physiology 226, 2139–2149 (2011). 
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4.1 Introduction 
Degenerative lesions in human valves are characterized by endothelial cell (EC) 
disruption, increased cellularity and extracellular matrix deposition, accumulation of 
oxidized lipoproteins, non-foam cell and foam cell macrophages, and occasional T cells 
within the valve interstitium2,3. These histological ﬁndings resemble early sclerotic 
lesions of the vasculature, and together with the shared risk factors, suggest that, as in 
atherosclerosis, the initiation of aortic valve sclerosis involves chronic inﬂammatory 
and neo-angiogenesis processes potentiated by systemic factors. 
Multiple biologic pathways are responsible for aortic valve degeneration. EC 
activation and neo-vascularization of the leaflets characterize the valve degeneration 
process since the aortic sclerosis phase. Pro-angiogenic factors are still detectable in the 
valve tissue when leaﬂet motion is impaired by calcium deposition4. The angiogenic 
process starts concomitantly with EC disruption, inﬂammation and lipid deposition5. 
Therefore, in the pathogenesis of calcific aortic valve disease (CAVD), injury to the 
endothelium is an important initial step causing thickening of the valve as a 
consequence of abnormal deposition of extracellular matrix, and thus preventing 
oxygen supply by diffusion. Decreased oxygen tension is a strong initiator of the 
angiogenic response through the induction of vascular endothelial growth factor 
(VEGF) gene expression6,7. The over-expression of VEGF receptors, Flk-1 and Flt-1, 
also increase with tissue hypoxia further supporting the importance of angiogenesis in 
the initiation and progression of CAVD. The endothelium lining the surface of valve 
leaﬂets is presumed to be involved in valve homeostasis and pathology. AVS leaflets 
show a stronger angiogenic response than control valve leaflets4,8-10.  
In this chapter, it is analyzed the role of osteopontin (OPN) in the regulation of 
EC activation in vitro and its role on excised tissues from AVS patients and controls. 
Studying the process of EC activation could bring to light important insights in the 
molecular mechanisms that drive the process of valve degeneration and help in the 
development of a therapeutic target before the calciﬁcation process occurs and surgical 
intervention becomes inevitable. 
 
 60 
4.2 Results 
4.2.1 Baseline patients characteristics 
On the total of 7 subjects, 43% were male. Their age was 61.3 ± 21.7 years. For 
the patients with AVS, the initial AVA was 0.8 ± 0.2, two had systemic hypertension, 
three had signiﬁcant coronary artery disease and one was a current smoker. All patients 
had a comprehensive echocardiographic assessment including, M-mode, two-
dimensional and color Doppler echocardiography. Table 4.1 further characterizes the 
study groups. Aortic valve calciﬁcation score was 3.5 ± 0.59 in AVS patients and 1.3 ± 
0.49 in controls (p < 0.001). 
 
Table 4.1. Patient demographics and Clinical details. 
Demographics 
Controls 
N=4 
Aortic 
sclerosis 
N=3 
Age (years) 48 ± 16 78.7 ± 14.8 
Male 1 (25.0%) 2 (66.7%) 
Smokers 0 (0.0%) 1 (33.3%) 
Hypertension 1 (25.0%) 2 (66.7%) 
Diabetes Mellitus 0 (0.0%) 0 (0.0%) 
Coronary Artery 
Disease 
0 (0.0%) 3 (100.0%) 
Hyperlipidemia 1 (33.3 %) 0 (0.0%) 
 
Adapted from11: Poggio, P. et al. Osteopontin controls endothelial cell migration in vitro and in excised 
human valvular tissue from patients with calcific aortic stenosis and controls. J. Cell. Physiol. 226, 2139–
2149 (2011). 
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4.2.2 Osteopontin promotes endothelial cell migration 
Since the endothelium is one of the primary targets during valve degeneration, 
we decided to characterize the EC response and to analyze the intracellular signaling 
pathway activated by in vitro OPN treatments. For the experiments we used human 
umbilical vein endothelial cells (HUVEC) due to the similarity to valve endothelial 
cells (VEC), in particular because the difficulty to obtain a homogeneous culture of 
VECs.  
To test the effect that OPN has on ECs, we implemented wound healing assays. 
After the confluent layer of ECs was scratch with a pipet tip to create the wound OPN 
was added to the media and plates were incubated at 37C. Differences in EC migration 
could be observed after 4 hours of treatment (not shown) and were evident after 24 
hours of treatment (Figure 4.1). As positive control 10% FBS was added to the media. 
These experiments conﬁrmed that OPN had an active role in promoting EC migration in 
vitro. 
 
Figure 4.1. OPN induces in vitro endothelial cell migration. 
(A) Wound healing assay of confluent HUVECs in the presence or absence of recombinant OPN (50 
ng/ml) analyzed after 24 hours. Magnification 4x. (B) Bar graph representation of endothelial cell 
migration. * p < 0.01. Adapted from11: Poggio, P. et al. Osteopontin controls endothelial cell migration in 
vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls. J. Cell. 
Physiol. 226, 2139–2149 (2011). 
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4.2.3 Endothelial cell migration induced by OPN require Erk1/2 
phosphorylation 
It has been reported that the positive effect of OPN on neovascularization is 
mediated by PI3K–Erk1/2 intracellular signaling pathway in vivo12. To test the 
intracellular signaling pathway that mediates EC migration, we ﬁrst analyzed the 
MAPK activation in the presence or absence of recombinant OPN. The MAPK proﬁle 
array shows signiﬁcant phosphorylation of Erk1/2 (Figure 4.2A). To conﬁrm this result, 
ECs were treated for 5’, 15’ 30’, and 60’ with recombinant OPN and then analyzed by 
Western blot with phospho-speciﬁc Erk1/2 antibodies (Figure 4.2B). Since this 
experiment show the activation of Erk1/2 intracellular signaling after OPN treatment, 
we used a common Erk1/2 chemical inhibitor (UO126) to test if Erk1/2 mediated EC 
migration in vitro. The analysis of wound closure after 24 hours of OPN treatment in 
presence of UO126 showed the abolishment of EC migration (Figure 4.2C and D).  
 
Figure 4.2. OPN promotes in vitro endothelial cell migration through Erk1/2 
phosphorylation. 
(A) Phospho-MAP kinase profile array of HUVECs treated with recombinant OPN (50 ng/ml) showing 
(p)ERK 1/2 activation. (B) Western blot for (p)ERK 1/2 of OPN-treated HUVECs. Tot ERK2 was used 
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to normalize the results and as a loading control. (C) Wound healing assay of confluent HUVECs treated 
with FBS10% as a positive control, and OPN (50 ng/ml) in the presence or absence of ERK1/2 chemical 
inhibitor UO126 (10 mM). Endothelial cell migration was photographed after 24 h at 4x magnification. 
(D) Bar graph representation of endothelial cell migration. * p < 0.01 and ** p < 0.01 vs. OPN treated. 
Adapted from11: Poggio, P. et al. Osteopontin controls endothelial cell migration in vitro and in excised 
human valvular tissue from patients with calcific aortic stenosis and controls. J. Cell. Physiol. 226, 2139–
2149 (2011). 
 
 
4.2.4 OPN biological activity is controlled by its phosphorylation status in 
endothelial cells 
To further characterize the role of OPN on the regulation of EC migration, we 
considered the effects of OPN post-translational modiﬁcations. Recombinant OPN was 
phosphorylated in vitro using casein kinase II (CKII) (Figure 4.3A). 
We treated EC for 24 hours and analyze wound healing in presence or absence 
of phosphorylated OPN and non-phosphorylated OPN. The results of this experiment 
demonstrated that phospho-OPN did not activate EC migration in vitro, whereas, 
dephosphorylated OPN promoted EC migration (Figure 4.3B and C).  
 
Figure 4.3. OPN phosphorylation status controls in vitro endothelial cell migration. 
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(A) Representative Western blot for OPN and phospho-threonine in the phosphorylated and non-
phosphorylated OPN recombinant used for the in vitro analysis. (B) Wound healing assay of confluent 
HUVECs in the presence or absence of recombinant OPN (50 ng/ml) or phosphorylated OPN (50 ng/ml) 
analyzed after 24 h. Magnification 4x. (B) Bar graph representation of endothelial cell migration. * p < 
0.01. Adapted from11: Poggio, P. et al. Osteopontin controls endothelial cell migration in vitro and in 
excised human valvular tissue from patients with calcific aortic stenosis and controls. J. Cell. Physiol. 
226, 2139–2149 (2011). 
 
 
4.2.5 Osteopontin, CD44 and αVβ3 interaction is essential for endothelial 
cell migration 
The primary receptors for OPN are those integrins that bind the central integrins 
attachment motif RGD. Since no speciﬁc OPN receptors have been identiﬁed so far, 
integrin αVβ3 was established as a primary receptor for OPN. In addition to the 
integrin binding, OPN also binds with a hyaluronic acid receptor, CD44 in an RGD-
independent manner13,14. 
Since both CD44 and αVβ3 can mediate the biologic activities of OPN, we ﬁrst 
analyzed the role of OPN on Erk1/2 activation in ECs in the presence or absence of 
neutralizing antibodies anti CD44 and αVβ3. We demonstrated that both neutralizing 
antibodies (CD44 and αVβ3) blocked Erk1/2 phosphorylation induced by OPN or 
phospho-OPN (Figure 4.4A). Then, we characterized the biological effects of these two 
neutralizing antibodies on EC migration. We performed wound healing assays on ECs 
under OPN treatment in presence or absence of neutralizing antibodies for CD44 and 
αVβ3. The neutralization of either CD44 or αVβ3 inhibited OPN effects on EC 
migration (Figure 4.4B and C). These results allowed us to demonstrate that 
dephosphorylated OPN induced EC migration through CD44 and αVβ3 activating the 
Erk1/2. 
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Figure 4.4. αvβ3 and CD44 are necessary for OPN-induced endothelial cell 
migration. 
(A) Western blot of total protein extract of HUVECs to test ERK1/2 phosphorylation under different 
treatments. From left to right: FBS10%, VEGF (30 ng/ml), untreated, OPN (50 ng/ml), (p)OPN (50 
ng/ml), UO126 (10 mM) in the presence of OPN or (p)OPN, neutralizing antibody for αvβ3  (10 mg/ml) 
in the presence or absence of OPN or (p)OPN and neutralizing antibody for CD44 (10 mg/ml) in the 
presence or absence of OPN or (p)OPN. (B) Wound healing assay of confluent HUVECs treated with 
OPN (50 ng/ml) in the presence of neutralizing antibody for CD44 or αvβ3. Endothelial cell migration 
was photographed after 24 hours at 4x magnification. (C) Bar graph representation of endothelial cell 
migration. * p < 0.01. Adapted from11: Poggio, P. et al. Osteopontin controls endothelial cell migration in 
vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls. J. Cell. 
Physiol. 226, 2139–2149 (2011). 
 
 
4.2.6 OPN controls endothelial cell migration of excised aortic valve 
through Erk1/2 
Angiogenesis is a key step in the remodeling of the aortic valve and the 
development of progressive valve calciﬁcation and degeneration. We decided to 
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investigate the response of excised aortic valve treated with OPN and its intracellular 
signaling pathways. To evaluate the ability of VECs to migrate and form tubular-like 
structures without any exogenous stimuli, leaﬂets derived from AVS patients and 
healthy controls were embedded in a 3D collagen type I matrix for 14 days. At day 14, 
formation of tubular-like structures was evaluated with a phase contrast microscope. 
From cultures of control leaﬂets, the endothelial migrating cells formed a monolayer 
around the valve tissue with few tubular-like structures. AVS-derived leaﬂets showed 
extensive tubular-like structures (Fig. 4.5A and B). 
To test if OPN has a similar effect on VECs embedded in 3D collagen, we 
repeated the cell sprouting assay in the presence or absence of OPN and we measured 
the cell number, migration distance and the formation of tubular-like structures of VECs 
derived from both AVS and control tissues. OPN promoted migration and tubular-like 
formation in our 3D assay, confirming the similarity between HUVECs and VECs. We 
then tested the effect of OPN on valve tissue to analyze the Erk1/2 mediate of the 
effects of OPN on VEC migration. OPN enhanced VEC migration into the 3D collagen 
matrix and UO126 blocked such migration. Together, these results suggest that both 
HUVECs and VECs were activated by OPN and that the activation is mediated by 
Erk1/2 intracellular signaling pathway. 
 
Figure 4.5. OPN induces in vitro angiogenesis of excised human aortic valve tissues 
through ERK1/2. 
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(A) In vitro angiogenesis assay of excised tissue from calcified (CAV) and non-calcified aortic valve 
(NCAV). (B) Bar graph representation of the in vitro angiogenesis assay. The number of tubular-like 
structures was counted as a number of branches per field. Pictures were taken at 10x magnification. (C) 
Non-calcified and calcified tissue embedded in collagen and treated with OPN in the presence or absence 
of UO126 (10 mM). (D) Bar graph representation of the in vitro angiogenesis assay. The number of 
tubular-like structures was counted as a number of branches per field. Pictures were taken at 10x 
magnification. * p < 0.01 and ** p < 0.01 vs. OPN treated. Adapted from11: Poggio, P. et al. Osteopontin 
controls endothelial cell migration in vitro and in excised human valvular tissue from patients with 
calcific aortic stenosis and controls. J. Cell. Physiol. 226, 2139–2149 (2011). 
 
 
4.2.7 CD44 and αVβ3 receptors controls endothelial cell migration of 
excised aortic valve 
Finally, we tested the role of both CD44 and αVβ3 on the formation of tubular-
like structures on aortic valve derived tissues. In accord with our in vitro experiments, 
both CD44 and αVβ3 are necessary for EC migration and collagen sprouting. With the 
3D assay we were able to demonstrate that the neutralization of either CD44 or αVβ3 
blocked the cellular reorganization into the collagen matrix when aortic valve leaflets 
were treated with OPN, and confirmed the inability to promote any VEC migration by 
the phosphorylated form of OPN (Figure4.6).  
 
Figure 4.6. αvβ3 and CD44 are necessary for OPN-induced in vitro angiogenesis of 
excised human aortic valve tissues. 
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(A) Bar graph representation of the in vitro angiogenesis assay on control tissues (NCAV). The number 
of tubular-like structures was counted as the number of branches per field. Pictures were taken at 10x 
magnification. (B) Bar graph representation of the in vitro angiogenesis assay on aortic stenosis tissues 
(CAV). The number of tubular-like structures was counted as the number of branches per field. Pictures 
were taken at 10x magnification. * p < 0.01 and ** p < 0.01 vs. OPN treated. Adapted from11: Poggio, P. 
et al. Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from 
patients with calcific aortic stenosis and controls. J. Cell. Physiol. 226, 2139–2149 (2011). 
 
 
 
4.3 Discussion 
OPN is a phosphorylated, acidic, RGD-containing glycoprotein that binds 
certain CD44 variants and integrin receptors, including αVβ315. OPN acts as a 
cytokine, playing important roles in the migration and invasion of several tumor 
cells16,17. In addition, OPN is regarded to be an important angiogenic factor in several 
pathologies. In this chapter it is described the biological effects of OPN in vitro and in 
excised aortic valve tissues. The results, combined with previously reported studies, 
conﬁrm that the biological function of OPN on aortic valve degeneration plays an 
important role on VECs. 
Calciﬁed aortic valve leaflets have also been shown to express neo-angiogenesis 
factors18. Although angiogenesis is considered to be part of the early stages of 
calciﬁcation, pro-angiogenic factors are expressed even when the valve is completely 
calciﬁed, suggesting that this mechanism is still present and active during the entire 
degeneration process.  
Correspondingly, it has been shown that ECs of stenotic but not those of non-
stenotic valves exhibit CEACAM1, a cell adhesion molecule expressed in angiogenic, 
but not in quiescent ECs9,19,20. Chalajour et al.9 have demonstrated that the formation of 
angiogenic sprouts from calciﬁed valves occurs signiﬁcantly faster than from non-
calciﬁed valves. Immunoreactivity of CD44 and vWF has been demonstrated in the 
tubular-like structures9. We reported the analysis on the role of OPN on cultured 
 69 
endothelial cells due to their physiological implication on the aortic valve leaﬂets. The 
comparison of the effects of OPN on aortic valve derived tissues form AVS patients and 
controls demonstrated that OPN activated the same intracellular signaling pathways in 
HUVECs and VEC from excised aortic valve tissues. 
Based on the presented results, EC migration of both HUVEC and aortic valve 
derived cells is dependent on CD44 and αVβ3 and results in Erk1/2 phosphorylation. 
Moreover, the OPN post-translational modiﬁcations are important in the ability to 
promote EC migration. These data provide new insights into the cellular and molecular 
mechanisms involving endothelial cells in stenotic aortic valve tissues. These results 
could bring new potential perspectives to the development of future preventive 
treatments for this condition. 
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Chapter 5 
 
Role Of Osteopontin In Valve Interstitial Cell 
Activation And Calcification 
 
Part of this chapter has been published as1,2: 
Paolo Poggio, Juan B. Grau, Benjamin C. Field, Rachana Sainger, William F. Seefried, 
Flavio Rizzolio, and Giovanni Ferrari. Osteopontin controls endothelial cell migration 
in vitro and in excised human valvular tissue from patients with calcific aortic stenosis 
and controls. Journal of Cellular Physiology 226, 2139–2149 (2011). 
 
Paolo Poggio*, Juan B. Grau*, Rachana Sainger, William J. Vernick, William F. 
Seefried, Emanuela Branchetti, Benjamin C. Field, Joseph E. Bavaria, Michael A. 
Acker, and Giovanni Ferrari. Analysis of Osteopontin levels for the identification of 
asymptomatic patients with calcific aortic valve disease. The Annals of Thoracic 
Surgery 93, 79–86 (2012). * These authors contributed equally to this work. 
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5.1 Introduction 
 The valve interstitial cells (VIC), a heterogeneous population, represent the 
majority of the cells within the valve leaflets. To further characterize the calcific aortic 
valve disease (CAVD), the role of osteopontin (OPN) has been analyzed in human 
derived aortic valve interstitial cells. The primary receptors for OPN, as previously 
discuss, are those integrins that present the central integrin binding motif RGD3. In 
addition to the integrin, the C-terminal fragment of OPN binds directly to CD44v6 in an 
RGD-independent manner3, inducing cell migration4,5. This receptor consists of 20 
exons, where the first five and the last five exons are constant and the others are present 
only in the variants. Exons 1 to 16 encode for the extracellular domain, exon 17 encodes 
for the transmembrane domain and the exons 18 and 19 encode for the cytoplasmic 
domain (Figure 5.1). The ten exons located between 5a to 14 are subjected to alternative 
splicing, resulting in the generation of CD44 variants. CD44 is a multifunctional 
receptor which plays a role in cell adhesion, cell traffic, presentation of chemokine and 
growth factors, transmission of growth signals and signals mediating hematopoiesis and 
apoptosis5.  
 
Figure 5.1. CD44 splicing variants. 
(A) Schematic structure of CD44s and CD44v that has an additional longer stem, which contains the 
variant exon(s). (B) CD44 gene consists of 20 exons, exons 1-5 (N-terminal domain) and exons 15-19 (C-
terminal domain). Exons 5a-14 (v1 to v10) generate CD44 variants through alternative splicing. 
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 This chapter investigates, ex vivo and in vitro, the role of OPN-CD44 functional 
interaction in the formation of calcium nodules in relation to the progression of CAVD. 
This part of the study was carried out using human derived smooth muscle cells (SMC), 
VICs and excised aortic valve leaflets, obtained through the heart transplant program 
and the cardiovascular surgery department. The preliminary experiments were tested on 
SMCs rather then VICs, since these two cell type share many molecular and 
physiological characteristics (Table 5.1). 
 
Table 5.1. Similarities between valve interstitial cells and smooth muscle cells. 
 VIC / SMC 
Morphology 
Resemble fibroblasts in morphology, being elongated and 
forming an orthogonal pattern of overgrowth post-confluence. 
Long cytoplasmic extensions, prominent adhesion and gap 
junctions, an incomplete basal lamina, and close association with 
the extracellular matrix6,7 
Markers 
expressed 
α-SMA8 
Vimentin9 
 
Adapted from1: Poggio, P. et al. Osteopontin controls endothelial cell migration in vitro and in excised 
human valvular tissue from patients with calcific aortic stenosis and controls. J. Cell. Physiol. 226, 2139–
2149 (2011). 
 
 
5.2 Results 
5.2.1 OPN biological activity is controlled by its phosphorylation status in 
smooth muscle cells 
To characterize the role of OPN on the regulation of VIC calcification, we 
implemented a calcification assay in combination with phospho-OPN or OPN not 
phosphorylated. In vitro inorganic phosphate (Pi) calcification assay has been 
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extensively used as a model to test the biological activity of proteins involved in the 
calcium deposition10,11, we tuned our calcification assay on SMCs. Recombinant OPN 
was phosphorylated in vitro using casein kinase II (Figure 5.2A) and its ability to 
control calcium deposition tested. Dephosphorylated recombinant OPN did not inhibit 
SMC biomineralization, while phosphorylated recombinant OPN inhibited calcium 
deposition in vitro (Figure 5.2B and C). These experiments confirm that the 
phosphorylation status controls the ability of OPN to inhibit biomineralization. 
 
Figure 5.2. OPN phosphorylation status controls in vitro smooth muscle cell 
calcification. 
(A) In vitro calcification of confluent smooth muscle cells treated with calcification medium (MEM 
containing 3 mM phosphate buffer) in the presence or absence of OPN (50 ng/ml) or (p)OPN (50 ng/ml). 
(B) Bar graph representation of total calcium expressed as calcium mg/ml of medium. * p < 0.01 and ** p 
< 0.01 vs. OPN treated. Adapted from1: Poggio, P. et al. Osteopontin controls endothelial cell migration 
in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls. J. 
Cell. Physiol. 226, 2139–2149 (2011). 
 
 
5.2.2 OPN-a, -b and -c inhibit biomineralization 
 OPN can be present in different isoforms and we decided to investigate the role 
of the three OPN isoforms -a, -b, and -c on a SMC in presence of Pi. Since OPN 
isoforms were not available for purchase, we cloned the three OPN isoforms in a 
bacterial expression plasmid (PGEX-5). Chimeric GST-Flag-tagged OPN isoforms 
were generated and purified (Chapter 2) (Figure 5.2A and B). In vitro calcification 
assay was performed when the cells were confluent in presence or absence of non-
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phosphorylated and phosphorylated OPN-a, -b and -c. All OPN splicing variants -a, -b, 
and -c were able to control in vitro biomineralization, inhibiting calcium deposition on 
SMCs surface only when they were in the phosphorylated form (Figure 5.3C and D). 
These results indicate that all the phosphorylated OPN splicing variants tested maintain 
the in vitro ability to inhibit calcium deposition induced by Pi treatments. Since the 
results between the three OPN isoforms are comparable we decided to use for the 
subsequent analysis the full-length recombinant OPN (OPN a). 
 
Figure 5.3 Osteopontin splicing variants and their role in cells biomineralization. 
(A) OPN splicing variant production and detection with Commassie blue staining. (B) OPN-a, OPN-b, 
and OPN-c expression detected by Western blot using anti-FLAG and anti-OPN antibodies. (C) Bar 
graph representative of calcium formed on vascular smooth muscle cells (SMC). (D) Calcification assay 
performed using OPN isoforms: (a, b) calcium accumulation on SMC cultured in normal media and in 
calcification media; (c, d, e) calcium deposition on SMC treated with calcification media in the presence 
of OPN isoforms non-phosphorylated; (f, g, h) calcium deposition on SMC treated with calcification 
media in the presence of phosphorylated OPN isoforms. Calcium accumulation was quantified and 
normalized against protein content. Adapted from2: Grau, J. B. et al. Analysis of osteopontin levels for 
the identification of asymptomatic patients with calcific aortic valve disease. Ann. Thorac. Surg. 93, 79–
86 (2012). 
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5.2.3 OPN controls smooth muscle cell calciﬁcation through CD44 and not 
αVβ3 
Since both CD44 and αVβ3 can mediate the biologic activities of OPN, in 
particular both receptor are required for ECs migration, we decided to further analyze 
the OPN interactions with CD44 and αVβ3 in SMCs and the intracellular signaling 
activated. 
Based on the previous results and to complete the in vitro characterization of 
OPN biological activity, we tested the protective biological activity of OPN using the 
same in vitro calciﬁcation assay in the presence or absence of UO126, and the 
neutralizing antibodies anti CD44 and αVβ3. The inhibition of Erk1/2 with the 
chemical inhibitor UO126 did not disrupt the protective effect of phospho-OPN in the 
in vitro calciﬁcation assay. We notice similar results by blocking the activity of αVβ3 
(Fig. 5.4). On the contrary, a neutralizing antibody anti CD44 was able to revert the 
inhibitory effects of OPN and allowed calcium deposition on the surface of cultured 
SMCs (Fig. 5.4). These experiments suggest that the protective effect of phosphorylated 
OPN was independent of Erk1/2 and mainly mediated by the activity of CD44.  
 
Figure 5.4. CD44 but not αvβ3 regulated (p)OPN-induced smooth muscle cell 
biomineralization. 
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(A) Phospho-MAP kinase profile array of human smooth muscle cells (SMC) treated with recombinant 
OPN (50 ng/ml) showing (p)ERK 1/2 activation. (B) In vitro calcification of confluent SMC treated with 
calcification medium (MEM containing 3 mM phosphate buffer) in the presence of the indicated 
treatments. (C) At day 8 of treatment, calcium was estimated using the calcium assay reagent. Amount of 
total calcium is expressed as calcium mg/ml of medium. Pictures were taken at 4x magnification. 
Adapted from1: Poggio, P. et al. Osteopontin controls endothelial cell migration in vitro and in excised 
human valvular tissue from patients with calcific aortic stenosis and controls. J. Cell. Physiol. 226, 2139–
2149 (2011). 
 
5.2.4 OPN-CD44 functional interaction as a hallmark of early stages of 
calcific aortic valve disease 
Based on the previous results we decide to better understanding the OPN-CD44 
interaction in human tissue and human isolated valve interstitial cells derived from 
healthy controls, AVSc and AVS patients. 
Upon informed consent, 27 patients were selected from our cardiac bioregistry. 
Four controls and 18 aortic valve sclerotic tissues were obtained through the heart 
transplant research program at the University of Pennsylvania Perelman School of 
Medicine. Five aortic valve stenotic tissues were collected during aortic valve 
replacement (AVR) procedures from patients with end-stage CAVD (Table 5.2). 
 
Table 5.2. Patient demographics and Clinical details. 
 Controls Aortic Sclerosis Aortic Stenosis 
Demographics N = 4 N = 18 N = 5 
Age 33.8 ± 12.2 58.8 ± 9.1 80.2 ± 7.0 
Male subjects 25% (1) 50% (9) 20% (1) 
Diabetes 25% (1) 28% (5) 20% (1) 
Hypertension 25% (1) 50% (9) 100% (5) 
Cerebral vascular accident 25% (1) 17% (3) 0% (0) 
Coronary artery disease 0% (0) 39% (7) 40% (2) 
Congestive heart failure 0% (0) 33% (6) 20% (1) 
Hyperlipidemia 0% (0) 33% (6) 80% (4) 
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In control aortic valves, both OPN and CD44 expressions were barely detectable 
throughout the entire leaflets (Figure 5.5A and B). In contrast, in sclerotic and stenotic 
aortic valves the expression of both proteins was higher when compared to healthy 
controls. Moreover, the stenotic tissues had a uniform expression, while the sclerotic 
ones had a major concentration of OPN and CD44 in the ventricularis region (Figure 
5.5A and B). To test ex vivo functional interaction, between OPN and CD44, Proximity 
Ligation Assay (PLA) was performed as described in Chapter 2. Reaction products (red 
dots), representing the direct binding between OPN and CD44, showed the functional 
interaction of these two proteins in both sclerotic and stenotic tissues. This particular 
interaction had approximately 10-fold increment, when compared to control aortic 
valves (Figure 5.5C and D). 
 
Figure 5.5. CD44-OPN functional interaction as a hallmark of early stages of 
calcific aortic valve disease. 
(A-B) Representative images showing histological analysis of human aortic valves (control, sclerotic and 
stenotic). Immunohistochemistry staining for CD44 and OPN. Bar represents 0.5 mm. (C) Proximity 
Ligation Assay (PLA), red fluorescence dots indicate reaction product showing extracellular binding 
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between CD44 and OPN. Magnification 100x. (D) Bar graph representing PLA quantification in control, 
sclerotic and stenotic aortic valves. * p value <0.05. 
 
Since bone morphogenetic protein 4 (BMP4) is known to be potent osteogenic 
morphogens present in ossified valves and directly affects osteogenic marker 
expression12,13, and mechanical stimulation is an important component of valve 
degeneration14-16, we decided to test whether OPN-CD44 binding was regulated by 
biomechanical stimulation. We therefore applied 15% stretch at 1Hz in the presence or 
absence of BMP4, using a tensile bioreactor to mimic the stress on the valve during the 
cardiac cycle (Chapter 2). As an internal control, native tissues were treated statically in 
the presence or absence of BMP4. Cyclic stretch of the leaflets did not damage leaflet 
morphology and maintains native ECM structure and cellular composition17,18. OPN-
CD44 binding was influenced only by BMP4, independently of the mechanical stimuli 
(Figure 5.6). 
 
Figure 5.6. CD44-OPN functional interaction in aortic valve sclerosis tissue under 
biomechanical stretch. 
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 (A) PLA showing CD44/OPN binding in aortic valve sclerotic tissue at 6 days under static or dynamic 
(15% stretch at 1 Hz) conditions ± BMP4 (100 ng/ml). (B) Bar graph represents PLA quantification. * p 
value <0.05. 
 
 
5.2.5 BMP4 induces OPN and CD44 binding in aortic valve sclerosis-
derived valve interstitial cells 
Since BMP4 alone was able to increase OPN-CD44 interaction, we tested the 
role of this interaction in the regulation of VIC osteogenic-like transdifferentiation and 
calcification deposition. We isolated primary interstitial cells from 10 patients (2 
controls, 4 sclerotic and 4 stenotic) according to the method described in Chapter 2. 
Phenotypic stability was assessed after isolation and isolated VICs were used between 
passage 2 and 4. It has been shown that OPN binds only the variants 3 and 6 of CD44 
(CD44v3 and CD44v6). We therefore tested whether these variants were present in 
aortic valve-derived VICs in our three cohorts of patients. All tested human isolated-
VICs expressed CD44v6 isoform, independently of the progression of the disease and 
no CD44v3 was detectable (Figure 5.7). 
 
Figure 5.7. CD44 variant expression in human isolated valve interstitial cells. 
PCR product obtained using primers for CD44v6 and CD44v3 on human isolated valve interstitial cells 
(VIC), 2 control, 4 sclerotic and 4 stenotic patients. GAPDH was used as internal control. 
 
In a time course experiment, we showed that in AVSc-derived VICs, the binding 
between OPN and CD44 is highly increased in response to BMP4 treatment. The PLA 
products (red dots), representing the interaction between the extracellular portion of the 
transmembrane receptor CD44 and OPN, increased after 4 hours of BMP4 treatment 
and persisted up to 6 days. A neutralizing antibody anti CD44 (NAb-CD44), 
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recognizing the epitope 2 (conserved region in the extracellular domain), compete with 
the OPN binding site to CD44 and could prevent the OPN-CD44 interaction (Figure 
5.8). 
 
Figure 5.8. CD44-OPN interaction on isolated VICs from asymptomatic AVSc 
patients. 
(A) Proximity Ligation Assay (PLA) showing CD44/OPN binding in aortic valve sclerotic valve 
interstitial cells (VIC) at 0h, 4h, 24h and 6 days after in vitro BMP4 treatments (100 ng/ml) ± NAb CD44 
(5 ug/ml). Magnification 100x. (B) Line graph represents PLA quantification * p value <0.05. 
 
 
5.2.6 OPN and CD44 interaction protects sclerotic valve interstitial cells 
from calcification induced by BMP4 
To link the OPN-CD44 interaction with calcium deposition, we treated isolated 
sclerotic VICs for 12 days in the presence or absence of BMP4. Using qPCR analysis, 
we evaluated the expression of OPN and ALP under BMP4 treatment to demonstrate its 
role in controlling the VIC activation towards an osteogenic-like phenotype. We noticed 
a significant up regulation of OPN by 3.3 ± 0.3 fold and ALP 2.2 ± 0.2 fold (p value < 
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0.05). To demonstrate the active role of endogenous OPN in protecting VICs from 
calcification, we checked presence of calcium deposition in AVSc-derived VICs treated 
with BMP4 for 12 days. Despite the increased level of ALP, AVSc-derived VICs did 
not show any sign of calcium accumulation. However, blocking OPN-CD44 interaction 
(by neutralizing antibody against either CD44 or OPN) induced calcium deposition, 3.4 
± 0.9 and 1.9 ± 0.2 fold increase, respectively when compared to BMP4 treatment alone 
(Figure 5.9). These results suggest the direct role of the functional interaction between 
OPN-CD44 in preventing calcium accumulation in AVSc-derived VICs. 
 
Figure 5.9. CD44 and OPN protect human sclerotic valve interstitial cells from 
calcification induced by BMP4. 
(A) Bar graphs represent fold change gene expression of OPN and ALP in aortic valve sclerotic valve 
interstitial cells (VIC) after 12 days in vitro treatment in the presence or absence of BMP4 (100 ng/ml). 
(B) Bar graph represents calcium deposition on aortic valve sclerotic VICs after 12 days treatment with 
BMP4 (100 ng/ml), NAb CD44 (5 ug/ml), NAb OPN (5 ug/ml), NI-IgG (5 mg/ml) and their 
combinations. * p value <0.05. (C) Alizarin red staining representing calcium deposition (red) on VICs 
after 12 days treatment with BMP4 (100 ng/ml), NAb CD44 (5 ug/ml), NAb OPN (5 ug/ml) and their 
combinations. 
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5.2.7 Akt phosphorylation induced by OPN-CD44 is required to protect 
sclerotic valve interstitial cells from calcium deposition 
Since the previous experiments on Erk1/2 did not show any link with calcium 
deposition, we investigated another intracellular signaling pathway activated OPN-
CD44 in human-derived VICs. Extensive work has reported a direct activation of 
MAPK signaling pathway by OPN in different cell lines4,19,20. We therefore decided to 
analyze Akt activation. Phosphorylation of SMAD1/5/8 was also tested as an 
independent signaling pathway activated by BMP4. In our experiment phospho-Akt is 
seen by Western blot after 15’, 4h and 24h of BMP4 and OPN treatments, however Akt 
phosphorylation is prevented by pre-treatment with a neutralizing antibody against 
CD44 (NAb-CD44). Furthermore, the phosphorylation of SMAD1/5/8 is BMP4 
dependent and the presence of NAb-CD44 does not affect SMAD phosphorylation 
(Figure 5.10). 
 
Figure 5.10. Akt phosphorylation induced by CD44/OPN. 
Western blot of pAkt, Akt 1/2, pSMAD 1/5/8 and GAPDH at 0h, 15’, 4h and 24h after BMP4 (100 
ng/ml) in combination with NAb CD44 (5 mg/ml) or NAb OPN (5 mg/ml). 
 
Since Akt was phosphorylated after BMP4 treatments, we evaluated the role of 
this phosphorylation, on regulating calcium deposition of VICs derived from AVSc 
patients. We therefore treated AVSc-derived VICs with BMP4 in the presence or 
absence of Wortmannin, a known phosphoinositide-3-kinase (PI3K)/Akt cascade 
inhibitor. The combination of BMP4 and Wortmannin resulted in an increment of 
calcium deposits measured by colorimetric assay by 2.7 ± 0.2 fold and by Alizarin red 
staining (Figure 5.11). These results suggest that Akt phosphorylation induced by OPN-
CD44 is required to protect human sclerotic valve interstitial cells from calcium 
deposition. 
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Figure 5.11. Akt phosphorylation is required to protect human sclerotic valve 
interstitial cells from calcium deposition. 
(A) Bar graph represents calcium deposition on aortic valve sclerotic VICs after 12 days treatment with 
BMP4 (100 ng/ml) ± Wortmannin (0.2 mM). * p value <0.05. (B) Alizarin red staining representing 
calcium deposition (red) on VICs after 12 days treatment with BMP4 (100 ng/ml) ± Wortmannin (0.2 
mM). 
 
 
5.3 Discussion 
Due to its asymptomatic presentation, little is known about the molecular 
mechanisms underlying tissue remodeling and VIC activation in aortic valve sclerosis 
patients. Here, we unveil the specific functional association of OPN with CD44v6 and 
the intracellular signaling mechanisms controlling calcium deposition on VIC derived 
from non-calcified AV tissues.  
High levels of OPN in native human calcified aortic valves from patients 
undergoing aortic valve replacements have been shown by immunohistochemistry, 
reverse transcription–polymerase chain reaction (RT-PCR), Western blotting, and in 
situ hybridization analyses4,19.  In addition to native valves, increased OPN levels were 
also found by immunohistochemistry in calcified valve allografts and in areas of 
calcification in glutaraldehyde-pretreated bioprosthetic porcine valves21,22. Elevated 
circulating OPN levels are also reported in other cardiovascular diseases, such as 
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atherosclerosis, ischemic heart disease, heart failure, and rheumatic mitral 
stenosis4.Osteopontin is of special interest for CAVD, since it is the only described 
biomarker directly involved in the ectopic and dystrophic calcification phenomenon that 
occurs during native and bio-prosthetic valve degeneration. Interestingly, circulating 
levels of OPN are also elevated in patients with signs of AVSc, suggesting that OPN 
could also be used as biomarker to label patients at risk to develop severe stenosis23. 
This chapter provides several new insights into the specific interaction of OPN 
with CD44 and the intracellular signaling controlling calcium deposition in human 
sclerotic-derived VICs. Tissue from early stages of AVSc is extremely difficult to 
obtain since these valves are mechanically functional and are not indicated for repair or 
replacement. However, our collaborations with the Gift of Life program and with the 
heart transplant program allow us to rely on this unique collection of human specimens. 
Using this major resource we demonstrated a specific OPN-CD44 functional interaction 
in early asymptomatic stage of CAVD. We then show, in vitro, that preventing OPN-
CD44 interaction result in calcium accumulation of VIC obtained from non-calcified 
AVSc patients after treatments with BMP4. Finally, using neutralizing antibodies and 
general inhibitors of intracellular signaling pathways we unveil that Akt 
phosphorylation induced by OPN-CD44 is required to protect human sclerotic valve 
interstitial cells from calcium deposition. The model depicted in Figure 5.12 provides 
novel insights into the intracellular mechanisms controlling OPN, and in general VIC 
activation and calcification, in human AVSc-derived cells. 
 
Figure 5.12. Summary scheme.  
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Chapter 6 
 
Osteogenic-like Activation Of Human Aortic Valve 
Interstitial Cells 
 
Part of this chapter has been published as1: 
Paolo Poggio, Rachana Sainger, Emanuela Branchetti, Juan B. Grau, Eric K. Lai, 
Robert C. Gorman, Michael S. Sacks, Alessandro Parolari, Joseph E. Bavaria, and 
Giovanni Ferrari. Noggin attenuates the osteogenic activation of human valve 
interstitial cells in aortic valve sclerosis. Cardiovascular Research 98, 402–410 (2013). 
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6.1 Introduction 
The aortic valve leaflets are a highly specialized structure consisting mostly of 
VICs and complex extracellular matrix (ECM) structures2-4. The leaflet is divided into 
three functionally specific layers. The fibrosa layer, facing the aorta, is primarily composed 
of type I collagen fibers with a strong preferred circumferential orientation. The 
ventricularis, facing the left ventricle, mainly consists of elastin and collagen. The 
spongiosa, located between the fibrosa and the ventricularis, is largely composed of 
glycosaminoglycans5. It has been speculated than valve interstitial cells (VIC) maintain 
valve tissue homeostasis through regulated ECM biosynthesis3. VICs appear to be 
phenotypically plastic as they transdifferentiate during valve development, disease and 
remodeling from a quiescent to an osteogenic-like phenotype6,7. The activation of VICs 
results in the expression of specific markers such as osteopontin (OPN), osteonectin (ON), 
runt-related transcription factor 2 (RUNX2), a-smooth muscle actin (SMA), osteocalcin 
(OCN) and alkaline phosphatase (ALP). Furthermore, activated VICs express and actively 
remodel fibronectin (FN), which is a major component of the insoluble ECM8. Bone 
Morphogenic Protein 2 and 4 (BMP2 and BMP4) are known to be potent osteogenic 
morphogens and to be present in ossified valves and directly affects osteogenic marker 
expression6,7,9-11. Furthermore, aortic valve leaflets are exposed to large cyclical stresses. 
During each cardiac cycle, the normally functioning aortic valve interacts closely with the 
surrounding environment and it is exposed to a myriad of mechanical forces such as 
transvalvular pressure, axial, shear and bending stresses, and cyclic flexure3,12-16. While 
normal hemodynamic forces have been shown to cause constant tissue renewal, altered 
mechanical forces are believed to induce changes in aortic valve biology that could 
possibly lead to valve disease2-4,17,18. 
Over the last decade, several clinical trials have been performed to try to halt 
the progression of calcific AVS. Early enthusiastic findings, documenting a reduction 
in the progression of the disorder, have been questioned by later randomized studies, 
which show substantial equivalence between treatments and placebo19-23. It has been 
proposed that the therapy may have been initiated too late in the course of the disease 
to be effective5,12,24.  
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In this chapter, it is investigated the mechanisms of human VIC activation in the 
very early stage of the disease using surgically resected aortic valve tissues and patient 
matched derived cells. Moreover, it is investigate the effect of HMG-CoA reductase 
inhibitor (pravastatin) on VIC osteogenic-like activation and calcium deposition. 
 
6.2 Results 
6.2.1 Patient population 
Fourteen controls, 32 AVSc, and 48 AVS patients were enrolled for this part of 
the study. After echocardiographic and exclusion criteria evaluations, described in 
Chapter 2, 14 controls, 17 AVSc and 29 AVS were further analyzed. Patient 
demographics and echocardiographic data are described in Table 6.1 and Table 6.2. 
 
Table 6.1 Patient demographics. 
Demographics 
Controls 
N = 14 
Aortic sclerosis 
N = 32 
Aortic stenosis 
N = 48 
Age 38.8 ± 15.8 57.8 ± 12.3 75.8 ± 7.9 
Male subjects 7 (58.3%) 13 (76.5%) 14 (48.3%) 
Smokers 4 (33.3%) 8 (47.1%) 14 (48.3%) 
Diabetes .. 3 (17.6%) 7 (24.1%) 
Hypertension 2 (16.7%) 9 (52.9%) 23 (79.3%) 
Cerebral vascular accident .. .. 1 (3.4%) 
Coronary artery disease 1 (8.3%) 2 (11.8%) 7 (24.1%) 
Congestive heart failure .. 12 (70.6%) 4 (13.8%) 
Hyperlipidemia 1 (8.3%) 6 (35.3%) 18 (62.1%) 
 
Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of human valve interstitial 
cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
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Table 6.2 Echocardiographic measurements 
 
Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of human valve interstitial 
cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
 
 
6.2.2 Analysis of aortic valve leaflet microstructure and extracellular 
matrix composition 
The histological analysis on 5 controls, 5 AVSc, and 5 AVS patients allowed us 
to measure the thickness of the leaflets, the number of cells and the extracellular matrix 
components (ECM) in the three different cohorts. 
In controls aortic valves the microstructure of the leaflets was defined in a 
distinctly organized tri-layered architecture (fibrosa, spongiosa and ventricularis). 
Sclerotic aortic valves had a partially modified tri-layer structure compered to the 
controls and AVSc leaflet thickness was significantly increased. Moreover, a slight 
reduction in the total number of cells was notice in AVSc tissue when compared to 
controls. In contrast to controls and AVSc, the AVS leaflet structure was completely 
disarrayed and a large loss of cells was observed (Figure 6.1A). Modified Movat’s 
Pentachrome staining was used to evaluate the ECM components, proteoglycan (bluish 
green), collagen (yellow), and elastin (dark violet). AVSc leaflets showed an increased 
ECM deposition; in particular we notice elastin deposition in the ventricularis layer of 
the leaflets. Tissues from AVS patients showed increased deposition of collagen, 
proteoglycan, and elastin fiber compared to controls and AVSc leaflets (Figure 6.1B). 
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We then investigated the presence of calcium deposits with Alizarin red staining. In 
controls and AVSc leaflets the staining was negative and the presence of calcium was 
comparable between the two groups. In contrast, in all the leaflets analyzed from aortic 
stenotic valves, calcium deposits were largely present and the distribution was mostly in 
the fibrosa layer (Figure 6.1C). 
 
Figure 6.1. Analysis of aortic valve sclerosis microstructure. 
(A, B, C) Representative images (n=5/group) for control, aortic valve sclerosis (AVSc), and aortic valve 
senosis (AVS) tissues: H&E staining; Movat’s Pentachrome staining: ECM components are distinguished 
as proteoglycan (bluish green), collagen (yellow), and elastin (dark violet); VIC nuclei are stained dark 
red. Alizarin red was used to visualize calcium content. F: fibrosa; S: spongiosa and V: ventricularis. Bar 
represents 0.5mm. Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of human 
valve interstitial cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
 
To better evaluate the ECM components among the three groups, we quantify 
type I collagen and two proteoglycans, decorin (DCN) and biglycan (BGN), by Real 
Time PCR (qPCR). Collagen type I was up regulated 7.5 ± 0.1 fold in AVSc vs. 
controls and 12.2 ± 0.1 fold in AVS vs. controls. Decorin was up regulated 17.8 ± 1.1 
fold in AVSc vs. controls and 19.3 ± 0.9 fold in AVS vs. controls. Biglycan was up 
regulated 18.1 ± 1.9 fold in AVSc vs. controls and 22.9 ± 1.2 fold in AVS vs. controls. 
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All the comparison were statistically different with a value p < 0.01 (Figure 6.2). 
 
Figure 6.2. Analysis of aortic valve sclerosis extracellular matrix. 
(D, E, F) Bar graph shows fold change gene expression of Decorin (DCN), Biglycan (BGN) and Collagen 
Type I (Col1A1) transcripts by RT-qPCR, respectively. Data were normalized against 18S gene 
expression and represented as fold change ± dCt SE. * p < 0.01. Adapted from1: Poggio, P. et al. Noggin 
attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis. Cardiovasc. 
Res. 98, 402–410 (2013). 
 
 
6.2.3 Osteogenic-like gene expression in aortic valve sclerosis tissues 
To better characterize the three cohorts we analyses 84 genes by RT2 PCR 
Array. The evaluated genes were related to ECM and cell adhesion molecules (CAM) 
and the complete list is reported in the Appendix A (Table 2). Among the genes up 
regulated more than two-fold, we validated the differential expression of 5 specific 
genes involved in the osteogenic-like transdifferentiation of valve interstitial cells (VIC) 
in 24 patients (8 controls, 8 AVSc, and 8 AVS). 
The relative expressions, in AVSc tissues compared to controls, were 10.5 ± 3.5 
fold for osteopontin (OPN), 11.9 ± 1.8 fold for osteonectin (ON), 10.6 ± 0.7 for fold 
thrombospondin 1 (THBS1), and 16.4 ± 1.1 fold for thrombospondin 2 (THBS2). AVS 
had a similar trend with a relative expression of 12.4 ± 4.1 fold for osteopontin (OPN), 
12.6 ± 2.1 fold for osteonectin (ON), 12.3 ± 0.9 for fold thrombospondin 1 (THBS1), 
and 20.6 ± 0.5 fold for thrombospondin 2 (THBS2), when compered to healthy controls. 
Runt-related transcription factor 2 (RUNX2) was diverging in AVSc and AVS tissues; 
in AVSc the expression was -2.5 ± 0.5 fold while in AVS was 3.8 ± 0.4 fold, when 
compared to controls. All the comparison were statistically different with a value p < 
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0.01 (Figure 6.3). We assessed by immunofluorescence RUNX2 levels to confirm the 
qPCR results. Comparable with the gene analysis, RUNX2 expression was detectable 
only in AVS tissues in all the three layers. (Figure 6.3) 
 
Figure 6.3. Osteogenic-like markers are up regulated in asymptomatic aortic valve 
sclerosis-derived tissues. 
Bar graphs show fold change gene expression of Osteonectin (ON), Thrombospondin 1 (THBS1), 
Thrombospondin 2 (THBS2), Osteopontin (OPN), and Runt-related Transcription Factor 2 (RUNX2). All 
RT-qPCR were normalized against 18S gene expression and represented as fold change ± dCt SE. * p < 
0.01. Lower panels represent immunofluorescence staining of RUNX2 on aortic valve tissues (red). 
Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of human valve interstitial 
cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
 
We also check for biosynthetically active VIC presence, the expression of alpha-
smooth muscle actin (SMA) was used as a marker of activated VICs. Western blot and 
immunofluorescence revealed an increased number of SMA positive VICs in the fibrosa 
layer of both AVSc and AVS leaflets (Figure 6.4). 
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Figure 6.4. Activated valve interstitial cells aortic valve sclerosis tissues. 
(A) Western blot of α-smooth muscle actin (SMA). (B) Immunofluorescence of SMA on aortic valve 
tissues. Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of human valve 
interstitial cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
 
Finally, since BMP4 is an inducer of osteoblastic differentiation, we tested 
whether BMP4 was also present and up regulated in our AVSc and AVS cohorts. 
Immunofluorescence and qPCR showed a significant up regulation in both AVSc and 
AVS tissues, 9.0 ± 0.9 fold and 12.4 ± 0.6 fold, respectively (p < 0.01). Interestingly, 
we notice a compelling BMP4 side-specific over expression correlating with the fibrosa 
susceptibility to form calcium deposits, typical of the late stage disease (Figure 6.5). 
 
Figure 6.5. BMP4 is up regulated in aortic valve sclerosis tissues. 
(A) Bar graph shows fold change gene expression of BMP4. RT-qPCR were normalized against 18S gene 
expression and represented as fold change ± dCt SE. * p < 0.01. (B) Immunofluorescence of BMP4 on 
aortic valve tissues. Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of 
human valve interstitial cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
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5.2.4 Role of BMP4 in osteogenic-like transdifferentiation of aortic valve 
sclerosis tissues 
Based on the obtained results, we decide to carry out in vitro and ex vivo 
experiments to determine the role of BMP4 in the osteogenic-like transdifferentiation of 
human aortic valve sclerosis-derived valve interstitial cells. 
To test the impact of BMP4 on AVSc-derived tissues we used a tensile 
bioreactor, to mimic the stress on the valve during the cardiac cycle we applied 15% 
stretch at 1 Hz. Since, Cyclic stretch does not damage leaflet morphology and maintains 
native ECM structure and cellular composition25,26, we tested VIC survival within the 
leaflets from controls, AVSc and AVS patients. TUNEL assay was used to evaluate the 
apoptotic VICs within the leaflets inserted in the bioreactor under static or dynamic 
conditions for 6 days. The stretch did not affect the controls and affected minimally 
AVSc- derived VICs. In contrast, a large number of VICs, within the leaflets excised 
from AVS patients and exposed to cyclic stretch, were found fluorescin positive, 
indicating the apoptotic nuclei (Figure 6.6). Due to the high apoptotic rate in AVS-
derived VICs and the relatively low access to control tissues we focus our analysis on 
aortic valve sclerosis-derived tissues and VICs. 
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Figure 6.6. Detection of apoptotic cells in aortic valve tissues exposed to tensile 
stretch. 
(A) TUNEL assay using native tissue analyzed after the excision of the tissue. (B) TUNEL assay using 
native tissue incubated in the bioreactor under dynamic condition after 6 days. Adapted from1: Poggio, P. 
et al. Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve 
sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
 
To evaluate VIC osteogenic-like transdifferentiation we measured the 
expression of alkaline phosphatase (ALP) by qPCR and the presence of calcium 
nodules by histological staining (Alizarin red). Interestingly, we found that only the 
combination of mechanical (15% stretch at 1 Hz) and biological (100 ng/ml BMP4) 
stimuli was able to stimulate ALP and calcium accumulation. ALP was up regulated by 
26.9 ± 0.7 fold (p < 0.01) in the native tissue under dynamic condition in the presence 
of BMP4, when compared to the tissue exposed to dynamic condition only (Figure 6.7). 
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Figure 6.7. BMP4 induces biomineralization of human aortic valve sclerosis tissue. 
(A) Immunohistochemistry staining with Alizarin red (to visualize calcium content) in aortic valve 
sclerosis (AVSc) tissue cultured in static and dynamic conditions in presence of osteogenic media (OS) ± 
BMP4 (100 ng/ml). * Represent the location of the fibrosa layer. (B) Alkaline Phosphatase (ALP) 
expression by RT-qPCR in native tissue cultured under dynamic condition in presence of OS ± BMP4 
(100 ng/ml). Data were normalized against 18S gene expression and represented as fold change ± dCt SE. 
* p < 0.05. Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of human valve 
interstitial cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
 
To further characterize the impact of BMP4 and mechanical stretch on the VIC 
activation, we tested the expression of SMA, FN, OPN, and ON. Protein expression 
revealed by immunofluorescence revealed a consistent overexpression of all the 
osteogenic markers tested.  As control and to provide supporting evidence for a direct 
functional role of BMP4 in inducing osteogenic-like activation of AVSc-derived VICs, 
we tested noggin (NOG), a known inhibitor of BMP4, in relation of VIC activation. 
NOG was able to reduce BMP4-mediated up regulation of ALP and OPN by 44.4% and 
64.3%, respectively (p < 0.05). Notably, we observed a NOG-related reduction of SMA 
and FN by 117% and 163%, respectively (p < 0.05) (Figure 6.8). 
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Figure 6.8. BMP 4 induces osteogenic markers expression in human aortic valve 
sclerosis tissue. 
(A) Immunofluorescence staining showing expression of α-Smooth Muscle Actin (SMA), Osteopontin 
(OPN), and Osteonectin (ON) in aortic sclerosis tissue cultured in static condition in presence of 
osteogenic media (OS) ± BMP4 (100 ng/ml). (B) Immunofluorescence staining showing expression 
SMA, Fibronectin (FN), OPN, and ON in AVSc tissue cultured in dynamic conditions in presence of OS 
± BMP4 (100 ng/ml). (C) SMA and FN expression by RT-qPCR in native tissue cultured under dynamic 
condition in presence of OS ± BMP4 ± Noggin (NOG) (500 ng/ml) *p<0.05. (D, E) Densitometry of 
OPN and Alkaline Phosphatase (ALP) expression by RT-qPCR in native tissue cultured under dynamic 
condition in presence of OS ± BMP4 (100 ng/ml) ± Noggin (NOG) (500 ng/ml). * p < 0.05. All RT-
qPCR analysis were normalized against 18S gene expression and represented as fold change ± dCt SE. 
OS was used to calculate the basal gene levels. Adapted from1: Poggio, P. et al. Noggin attenuates the 
osteogenic activation of human valve interstitial cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–
410 (2013). 
 
 
5.2.5 Activation of isolated valve interstitial cells by BMP4 
Our results, on tissues from asymptomatic patients with aortic sclerosis, showed 
that we could induce osteogenic-like transdifferentiation of VICs. To better understand 
the VIC activation, we sought to test isolated patient-derived cells and we conducted the 
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experiment using collagen type I-coated plates. BMP4 treatment in OS media showed 
up regulation of OPN, RUNX2, and ON only in control-derived VICs by 7.63 ± 0.6, by 
5.36 ± 0.6, and by 3.44 ± 0.2 fold, respectively (P < 0.05), and NOG was able to 
counteract the BMP4 effect. Contrarily, AVSc- and AVS-derived VICs showed no 
significant up regulation in RUNX2 and ON. OPN was upregulated by 2.1 ± 0.2 in 
AVSc-derived VICs but not in AVS-derived VICs (Figure 6.9). As previously discuss 
in chapter 5, treatment with BMP4 were not able to induce any calcium accumulation 
during the timeframe of the experiments.  
 
Figure 6.9. Activation of valve interstitial cells after BMP4 treatments. 
(A, B, C) Bar graphs represent fold change gene expression of Osteopontin (OPN), Runt-related 
transcription factor 2 (RUNX2) and Osteonectin (ON) in vitro treatment in presence of osteogenic media 
(OS) ± Bone Morphogenetic Protein 4 (BMP4) (100 ng/ml) ± Noggin (NOG) (500 ng/ml) in control, 
aortic valve sclerosis (AVSc) and Aortic Valve Stenosis (AVS) derived VICs plated on collagen type I. * 
p < 0.05. Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of human valve 
interstitial cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
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In order to discern the progression of aortic valve sclerosis to stenosis, we 
implemented a tissue engineered (TE) model to test the impact of the combinatory 
effect of BMP4 and mechanical stimulation on isolated VICs derived from AVSc 
patients. VICs derived from AVSc patients were seeded on the TE model based on a 
decellularized porcine aortic valve. TE aortic valves were placed in the tensile stretch 
bioreactor and exposed to mechanical stretch in presence or absence of BMP4 or in 
presence of a combination of BMP4 and NOG for 6 days. In contrast to the VIC 
cultured in plated, the AVSc-derived VICs embedded in the TE valves exhibited a 
significantly up regulation of the osteogenic markers analyzed. SMA, OPN, ON, and 
RUNX2 were up regulated by 1.94 ± 0.1, by 2.28 ± 0.3, by 3.17 ± 0.3, and by 3.22 ± 
0.2 fold, respectively (P < 0.05). NOG treatments completely reverted SMA, ON, and 
RUNX up regulation, furthermore NOG reduced the expression of OPN by -4.11 ± 0.2 
folds (P < 0.05) (Figure 6.10). 
 
Figure 6.10. Noggin attenuates BMP4-induced activation of human valve 
interstitial cell in asymptomatic aortic valve sclerosis. 
(A) Decellularized porcine Aortic Valve (AV) scaffold. (B) H&E staining showing the presence or 
absence of Valve Interstitial Cells (VIC) in the native porcine aortic valve (Native), after decellularization 
(Decell) and after reseeding of human VICs (Recell). (C) Immunofluorescence staining showing 
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expression of α-Smooth Muscle Actin (SMA), OPN, ON and RUNX2 in AVSc tissue cultured in 
dynamic conditions in presence of OS ± BMP4 (100 ng/ml). (D) SMA, OPN, ON and RUNX2 
expression by RT-qPCR in tissue engineering tissue cultured under dynamic condition in presence of OS 
± BMP4 (100 ng/ml) ± Noggin (NOG) (500 ng/ml). All RT-qPCR analysis were normalized against 18S 
gene expression and represented as fold change ± dCt SE. * p < 0.05. OS was used to calculate the basal 
gene levels. Adapted from1: Poggio, P. et al. Noggin attenuates the osteogenic activation of human valve 
interstitial cells in aortic valve sclerosis. Cardiovasc. Res. 98, 402–410 (2013). 
 
 
6.2.6 Valve interstitial cells phenotypic changes induced by Pravastatin  
 Since we demonstrated that AVSc-derived tissues and cells show over 
expression of osteogenic markers compared to healthy controls, we tested the effect of 
pravastatin on VIC phenotype changes. Ex vivo tissues derived from AVSc patients 
were placed in the bioreactor and subjected to tensile stretch in presence or absence of 
100 µM pravastatin. After 6 days of treatments, qPCR analysis showed a down 
regulation of SMA, OPN, ON, and RUNX2 by -4.49 ± 1.2, by -1.83 ± 0.9, -4.72 ± 0.4, 
and by -4.44 ± 0.2, respectively (p < 0.05) (Figure 6.11). 
 
Figure 6.11. Statin treatment of aortic valve sclerosis tissue. 
Bar graphs show fold change gene expression of SMA, OPN, RUNX2, and ON. All RT-qPCR were 
normalized against 18S gene expression and represented as fold change ± dCt SE. * p < 0.01. 
 
To further investigate the effect of pravastatin, we treated isolated VICs from 
controls, AVSc and AVS patients. We noticed a different response in the three groups, 
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VICs derived from healthy controls were unresponsive to pravastatin, while AVSc- and 
AVS-derived VICs had opposite results. VICs isolated from AVSc patients showed a 
significant down regulation of SMA, RUNX2, ON, and OCN by -2.3 ± 0.4, by -1.3 ± 
0.4, by -2.2 ± 0.2, and by -1.7 ± 0.3 fold, respectively (p < 0.05). Interestingly, we 
notice a significant up regulation of osteogenic markers in AVS-derived VICs after 
pravastatin treatments, SMA by 2.7 ± 0.4 fold, RUNX2 by 3.2 ± 0.3 fold, ON by 2.9 ± 
0.4 fold, and OCN by 3.1 ± 0.4 fold (p < 0.05) (Figure 6.12). 
 
Figure 6.12 Statin treatment of isolated valve interstitial cells. 
Bar graphs show fold change gene expression of SMA, OPN, RUNX2, and ON. All RT-qPCR were 
normalized against 18S gene expression and represented as fold change ± dCt SE. 
 
 
6.3 Discussion 
To impact the progression of calcific aortic valve disease (CAVD), we need to 
understand the earliest stages of this pathology in order to measure the effects of 
 106 
targeted therapy on the microscopic processes in the valve leaflets. Despite recent 
efforts, progress to understand, diagnose, and treat calcific aortic valve stenosis (AVS) 
have been hindered by our inability to resolve the cellular mechanisms leading VIC 
activation towards an osteogenic-like phenotype24,27,28. We performed an analysis of 
aortic valve leaflets and patient-matched derived VICs using control, AVSc, and AVS 
patients. Notably, the valve mechanical functions of aortic sclerosis are largely 
unaffected; patients with aortic sclerosis have similar aortic valve area (AVA) and 
Doppler velocity values when compared with controls. Accordingly, aortic sclerosis 
patients are largely asymptomatic and are not indicated for aortic valve replacement 
(AVR). Therefore, we established collaboration with the heart transplant program that 
allowed us the use of either hearts of donors that were not used for transplantation or 
from recipients that, although transplanted, had a normally functioning aortic valve. 
Our study provides several new insights into the early pathogenesis and the 
progression of AVSc. First, our data show that aortic valve leaflets form AVSc patient 
shows extensive ECM remodeling even in the absence of biomineralization. These 
events are associated with activation of VICs towards an osteogenic-like phenotype 
associated with up regulation of BMP4. Taken together, these results show that aortic 
sclerosis could be considered, from the cellular and molecular point of view, a 
pathological stage. Secondly, the results demonstrate that non-calcified aortic valve 
leaflets from asymptomatic patients can be induced to express markers of osteogenic 
transdifferentiation under the combinatory effect of biological (BMP4) and mechanical 
(tensile stretch) forces. Recent studies on aortic valve disease have described the 
expression of developmental genes in areas of valve calcification; thereby supporting 
the idea that valve calcification is not a passive deposition of calcium, but is actively 
regulated by a hierarchy of signaling pathways and transcription factors. Among these, 
BMPs signaling is important for valvulogenesis and osteogenesis and it is increased 
during AVS29,30. Recent manuscripts suggest a regulatory mechanisms of the BMP 
family in controlling osteogenic phenotype under mechanotrasduction stimulation31-33. 
BMP4 is essential in the osteochondrogenic gene program associated with vascular and 
valve calcification34,35. However, the factors that regulate mineralization in aortic 
diseases are poorly understood. Here, we reported the up regulation of SMA, OPN, 
RUNX2, and ON during the progression of calcific AVS. Furthermore, we observe the 
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fibrosa-layer susceptibility of non-calcified aortic sclerosis tissue to undergo 
biomineralization similarly to the natural course of the pathology. The deposition of 
calcium on the aortic side of aortic sclerosis tissue is likely due to the presence of 
nucleation centers, which provide the starting point for calcium nodule formation36. 
Notably, VIC transdifferentiation towards an osteogenic-like phenotype characterized 
by SMA, FN, OPN, and ALP overexpression are reduced by BMP4 antagonist NOG. 
We also implemented a TE model to demonstrate that human isolated VICs could be 
seeded in 3D scaffold and the biomechanical stimuli induced the transdifferentiation of 
the seeded VICs. This model allowed the used of human VIC in a controlled 3D 
environment and could be used to further characterize the osteogenic-like 
transdifferentiation. Of note, when using the TE model, we do not see calcium 
accumulation, which could be explained by the short duration (6 days) of the 
experiment and by the lacking of center of nucleation. 
 Despite the high prevalence of CAVD, no pharmacological treatment has 
been found to halt the progression of this degenerative pathology19,21,23. It has been 
hypothesized that the therapy has been initiated too late in the course of the disease5. 
Our results showed that statins were able to reduce the activation of VIC derived from 
aortic valve sclerosis patients. Additionally, this reduction was more pronounced using 
our ex vivo model based on AVSc excised tissues. In conclusion, our data support the 
hypothesis that statin treatments could be beneficial for patients in the early 
asymptomatic phase of CAVD. Therefore, new clinical trials should be designed to test 
the impact of lowering lipid therapy to halt the progression of this disease in its earliest 
phase. 
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Chapter 7 
 
Conclusion 
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7.1 Calcific aortic valve disease 
Calcific aortic valve disease (CAVD) is the most common heart valve disease 
with a prevalence of ≈ 30% in adults over 65 years in the sub-clinical asymptomatic 
form, called aortic valve sclerosis (AVSc)1. Importantly, between 16% and 33% of 
patients with AVSc will progress to aortic valve stenosis (AVS)2,3, the most common 
cause of sudden death among valve heart diseases4. Moreover, the incidence of CAVD 
continues to rise due to the aging population5, as such, calcific aortic valve disease has a 
serious impact on general health. AVSc is characterized by thickening of the leaflets 
with none or marginal effect on the mechanical properties of the valve, making its 
presentation largely asymptomatic6. Almost 10% of these patients will progress to AVS, 
the end stage disease, which is associated with impaired leaflet motion and resistances 
to blood flow1. At the onset of mild symptoms of AVS, survival deviates considerably 
from the event-free curve, with a dramatic decline with severe AVS7,8. Therapeutic 
strategies able to reduce or halt the progression of CAVD are needed, but currently no 
pharmacological therapies has been successful leaving aortic valve replacement (AVR) 
the treatment of choice. 
 
1. Could osteopontin be used as biomarker for early detection of calcific aortic 
valve disease? 
 
Since the presence of AVSc has been associated with a higher risk of 
cardiovascular events, early identification of these patients will open new perspectives 
for early therapeutic intervention. It has been previously reported that circulating OPN 
levels are elevated in aortic valve stenosis (AVS) patients when compared to healthy 
controls9. Since the biological function of OPN is to regulate calcium deposition10, it 
has been proposed that the increasing levels of OPN in diseased tissue and blood 
reflects a compensatory mechanism. We confirmed that OPN expression increased from 
control to AVSc and AVS derived tissues. We demonstrated an up regulation of plasma 
OPN levels derived from AVSc patients with no signs of aortic calcification compared 
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to healthy controls. Moreover, in the plasma of end-stage disease patients we found 
increased levels of OPN, which showed reduced phosphorylation at two tyrosine 
residues. Finally, OPN splicing variants -a, -b, and -c were differentially expressed 
during CAVD progression. These data indicate the possible use of OPN and its 
translational/post-translational modifications as possible biomarker for the identification 
of early phase of CAVD, in patients with no chronic inflammation or active 
malignancy. 
 
2. Which is the role of osteopontin in valve endothelial cell migration? 
 
Early aortic lesions seem to be initiated by increased mechanical or decreased 
shear stress, in combination with endothelial dysfunction, which is followed by lipids 
deposition11. Valve endothelial cell (VEC) activation and neo-vascularization of the 
leaflets characterize the valve degeneration process beginning in the aortic sclerosis 
phase11. Since OPN is overexpressed in CAVD patients and the endothelium is one of 
the primary targets during valve degeneration, we decided to characterize the VEC 
intracellular signaling pathway activated by OPN, using in vitro and ex vivo approaches. 
The experiments performed have demonstrated that OPN is able to regulate the EC 
migration through Erk1/2 phosphorylation. Moreover, we had shown the involvement 
of the both αvβ3 and CD44, two major OPN receptors, in the wound healing process. 
Interestingly, we noticed that dephosphorylated OPN but not the phosphorylated form, 
was able to stimulate EC migration. To further analyze the role of OPN in neo-
vascularization we implemented a 3D system, where excised human aortic valve tissues 
were embedded in collagen. AVS-derived tissues were more prone to develop new 
tubular-like structure than healthy valves. Non-phosphorylated OPN was able to further 
increase the sprout of tubular-like structure from AVS-derived tissues through αvβ3 
and CD44 and subsequent Erk1/2 phosphorylation. 
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3. What is the role of osteopontin in valve interstitial cell osteogenic-like 
activation and biomineralization? 
 
Considering that valve interstitial cells (VIC) represent the majority of the cells 
within the valve leaflets and that VIC are prone to calcification when activated, we 
decided to evaluate the role of OPN on VIC osteoblastic-like activation and 
biomineralization. First of all, we characterize which form of OPN was involved in 
calcium deposition. We demonstrated that all of the splicing variants tested were able to 
inhibit calcium accumulation only when they were phosphorylated. Moreover, the 
protective effect of phosphorylated OPN was independent of αvβ3 and Erk1/2 
activation. The OPN protective effect was mainly mediated by the activation of CD44 
and the phosphorylation of Akt. To further analyze the cause of VIC activation and 
subsequent calcification, we investigated the BMP4 signaling pathway. With this set of 
experiments, we were able to demonstrate that BMP4 was responsible for the 
osteogenic-like transdifferentiation. Furthermore, the OPN-CD44 functional interaction 
was able to prevent biomineralization induced by BMP4. 
Significantly, OPN post-translational modification and interaction with different 
receptors are able to activate different signaling pathways on different cell population. 
Non-phosphorylated OPN induces VEC migration through αvβ3 and CD44 
engagement and phospho-Erk1/2, while phosphorylated OPN inhibits VIC calcium 
accumulation through CD44v6 activation and phospho-Akt. 
 
4. Is it possible to analyze cell behavior while preserving the specialized aortic 
leaflet architecture? 
 
The aortic valve has a highly specialized architecture with a complex extracellular 
matrix (ECM)12-14. In controls aortic valves the microstructure of the leaflets was 
defined in a distinctly organized tri-layered architecture, while the AVSc leaflets had a 
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partially modified tri-layer structure. Notably, the thickness of AVSc leaflets was 
significantly increased. Moreover, AVS leaflet structure was completely disarrayed, a 
large loss of cells was observed and massive calcium deposits were found. Interestingly, 
a significant up regulation of BMP4 and SMA was found in AVSc- and AVS-derived 
tissues. We also noticed SMA positive VIC presence only in the aortic side and the 
fibrosa layer, which is more prone to develop calcium accumulation. Taken together, 
these results indicate a side specific osteogenic-like activation in the early phase of 
CAVD. Furthermore, aortic valve leaflets are exposed to large cyclical stresses. During 
each cardiac cycle, the normally functioning aortic valve interacts closely with the 
surrounding environment and it is exposed different mechanical forces13,15-17. To better 
understand the complexity of the disease, we implemented a tensile stretch bioreactor able to 
maintain the integrity of the leaflet structure. The bioreactor allowed us to test biological 
stimuli in combination with mechanical forces. We were able to test excised tissues derived 
from controls, AVSc and AVS patients, but we further analyzed only AVSc tissues because 
of the rarity of control tissues and because AVS tissues were not suitable to be adapted to the 
tensile bioreactor. Implementing this ex vivo model, we were able to demonstrate that AVSc 
tissues could be induced to express advanced osteogenic marker and furthermore, these 
tissues developed calcium accumulation in the fibrosa layer. We also implemented a tissue 
engineering (TE) model to demonstrate that isolated human VICs could be genetically 
manipulated and subsequently seeded in a 3D scaffold. Finally, the combination of 
biological and mechanical stimuli induced the osteogenic-like transdifferentiation of the 
seeded VICs. 
 
5. Can statins be effective on the early stage of calcific aortic valve disease? 
 
Over the last decade several clinical trials, mostly extensions of atherosclerosis-
related studies (collectively referred as “statin trials”), have been performed in order to 
study the impact on the progression of calcific aortic valve disease (CAVD) but 
generated contradictory results. The early enthusiastic findings documenting a reduction 
in the progression of CAVD have been questioned by more recent randomized studies, 
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which showed substantial equivalence between treatments and placebo18-22. It has been 
suggested that CAVD therapy in these trials may have been initiated too late in the 
course of the disease to be effective16,23-25. In addition, human aortic sclerotic tissues are 
generally not available to investigators since these valves are not surgically replaced 
until moderate to severe aortic stenosis occurs26-30. We now understand that AVS is just 
the end-stage of a disease that progresses from the microscopic early changes of aortic 
sclerosis to, in a subset of patients, asymptomatic and then symptomatic severe calcific 
stenosis. In vitro and in vivo studies have shown that valve calcification is an active 
process controlled by inflammatory mediators and regulators of osteogenic-like 
differentiation of VIC in the fibrosa layer of leaflets. Here, we have investigated the 
early asymptomatic stage of CAVD using a human bio-registry of tissue and VIC-
derived cells6,31-33. Furthermore, we studied the effect of pravastatin on human isolated 
VICs derived from controls, AVSc and AVS patients and finally we tested the effect of 
pravastatin on AVSc excised tissues under mechanical stretch. Our results indicate that 
statin treatments are able to reduce the activation of VIC derived from aortic valve 
sclerosis patients. This reduction was more pronounced using our ex vivo model based 
on AVSc excised tissues. Interestingly, VICs isolated from healthy controls were 
unresponsive to the statin treatments; while VICs derived from AVS patients had an 
even greater increase in osteogenic marker expression. In conclusion, our data support 
the hypothesis that statin treatments could be beneficial for patients in the early 
asymptomatic phase of CAVD. Therefore, new clinical trials should be designed to test 
the impact of lowering lipid therapy to halt the progression of this disease in its earliest 
phase. 
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Appendix A 
Table 1. List of Primers used. 
 
  
Gene   Primer sequence  
BMP4 
Fw  5'- CAC TGG TCC CTG GGA TGT TC -3' 
Rv  5'- GAT CCA CAG CAC TGG TCT TGA CTA -3' 
ON 
Fw  5’- GAG AAA GAA GAT CCA GGC CC -3’ 
Rv  5’- GCC TGT CTC TAA ACC CCT CC -3’ 
OPN 
Fw  5'- TTG CAG CCT TCT CAG CCA A -3'  
Rv  5'- GGA GGC AAA AGC AAA TCA CTG -3'  
RUNX2 
Fw  5’- CCA ACC CAC GAA TGC ACT ATC -3’  
Rv  5’- TAG TGA GTG GTG GCG GAC ATA C -3’  
ALP 
Fw 5’- GCT GGC AGT GGT CAG ATG TT -3’ 
Rv 5’- CTA TCC TGG CTC CGT GCT C -3’ 
FN 
Fw 5’- CCG TGG GCA ACT CTG TC -3’ 
Rv 5’- TGC GGC AGT TGT CAC AG -3’ 
THBS1 
Fw 5’- CAC AGC TCG TAG AAC AGG AGG -3’ 
Rv 5’- CAA TGC CAC AGT TCC TGA TG -3’ 
THBS2 
Fw 5’- GCA GCG TCT CTG TGT TCT CA -3’ 
Rv 5’- GAG TCA CTT CAG GGG TTT CG -3’ 
Col1A1 
Fw 5’- GGA CAC AGA GGT TTC AGT GG -3’ 
Rv 5’- CCA GTA GCA CCA TCA TTT CC -3’ 
DCN 
Fw 5’- ATC CTC CTT CTG CTT GCA CA -3’ 
Rv 5’- TGC TCC AGG ACT AAC TTT GCT -3’ 
BGN 
Fw 5’- CCC TCT CCA GGT CCA TCC GC -3’ 
Rv 5’- GAG CTG GTA GGT TGG GCG GG -3’ 
CD44v6 
Fw 5’- TCC CAG TAT GAC ACA TAT TGC -3’ 
Rv 5’- CCC ACA TGC CAT CTG TTG CC -3’ 
CD44v3 
Fw 5’- TCC CAG TAT GAC ACA TAT TGC -3’ 
Rv 5'- TCA TTT GGC TCC CAG CCT GG -3' 
GAPDH 
Fw 5’-  CCCATCACCATCTTCCAGGAG -3’ 
Rv 5’-  CTTCTCCATGGTGGTGAAGACG -3’ 
18S 
Fw 5’- GTA ACC CGT TGA ACC CCA TT -3’ 
Rv 5’- CCA TCC AAT CGG TAG TAG CG -3’ 
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Table 2. RT2Profiler PCR Array list of genes analyzed. 
 
 
